Skip to content
2000
image of Germline-Targeting Strategies to Induce bNAbs against HIV-1
file format pdf download PDF

Abstract

Developing an effective HIV-1 vaccine remains a critical global health challenge, hindered by the virus’s high genetic diversity, immune evasion strategies, and structural complexity of its Envelope (Env) glycoprotein. Broadly neutralizing antibodies (bNAbs), capable of targeting conserved Env epitopes, offer a promising path for vaccine design. Germline-Targeting (GT) strategies have emerged as a promising approach to engage naive B cell precursors that have the potential to mature into bNAb-producing cells. Advances in GT have enabled the design of immunogens capable of recruiting specific bNAb precursors in animal models and early clinical trials. Despite these successes, achieving neutralization breadth requires sequential immunizations with tailored boosting strategies to guide B cell maturation. Studies underscore the importance of using immunogens that mimic native Env structures while modulating glycosylation patterns to focus immune responses. Emerging approaches, such as membrane-bound presentation and mRNA delivery, hold the potential for enhancing immunogen effectiveness and rapid pre-clinical and in human screening to identify combinations of immunogens that foster bNAb lineages. This review seeks to synthesize key developments in GT strategies for HIV-1 vaccines, highlighting the design and implementation of immunogens that drive bNAb precursor maturation. It aims to underscore the importance of integrating structural insights, immunogen sequence design, and delivery methods to enhance the induction of bNAbs, offering direction for future research to address existing gaps and optimize vaccine efficacy.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X365229250527111140
2025-06-10
2025-10-28

  • From This Site

    /content/journals/chr/10.2174/011570162X365229250527111140
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/chr/10.2174/011570162X365229250527111140/BMS-CHIVR-2024-HT10-6091-10.html?itemId=/content/journals/chr/10.2174/011570162X365229250527111140&mimeType=html&fmt=ahah

References

  1. Fischer W. Giorgi E.E. Chakraborty S. Nguyen K. Bhattacharya T. Theiler J. Goloboff P.A. Yoon H. Abfalterer W. Foley B.T. Tegally H. San J.E. de Oliveira T. Gnanakaran S. Korber B. Wilkinson E. Msomi N. Iranzadeh A. Fonseca V. Doolabh D. Mlisana K. von Gottberg A. Walaza S. Allam M. Ismail A. Mohale T. Glass A.J. Engelbrecht S. Van Zyl G. Preiser W. Petruccione F. Sigal A. Hardie D. Marais G. Hsiao M. Korsman S. Davies M-A. Tyers L. Mudau I. York D. Maslo C. Goedhals D. Abrahams S. Laguda-Akingba O. Alisoltani-Dehkordi A. Godzik A. Wibmer C.K. Sewell B.T. Lourenço J. Pond S.L.K. Weaver S. Giovanetti M. Alcantara L.C.J. Martin D. Bhiman J.N. Williamson C. Network for Genomic Surveillance in South Africa (NGS-SA) HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host Microbe 2021 29 7 1093 1110 10.1016/j.chom.2021.05.012 34242582
    [Google Scholar]
  2. Korber B. Hraber P. Wagh K. Hahn B.H. Polyvalent vaccine approaches to combat HIV ‐1 diversity. Immunol. Rev. 2017 275 1 230 244 10.1111/imr.12516 28133800
    [Google Scholar]
  3. Kelsoe G. Haynes B.F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 2017 275 1 79 88 10.1111/imr.12508 28133807
    [Google Scholar]
  4. Haynes B.F. Verkoczy L. AIDS/HIV. Host controls of HIV neutralizing antibodies. Science 2014 344 6184 588 589 10.1126/science.1254990 24812389
    [Google Scholar]
  5. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010 8 1 55 67 10.1016/j.chom.2010.06.004 20638642
    [Google Scholar]
  6. Watanabe Y. Bowden T.A. Wilson I.A. Crispin M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim. Biophys. Acta, Gen. Subj. 2019 1863 10 1480 1497 10.1016/j.bbagen.2019.05.012 31121217
    [Google Scholar]
  7. Whitney J.B. Lim S.Y. Osuna C.E. Kublin J.L. Chen E. Yoon G. Liu P.T. Abbink P. Borducci E.N. Hill A. Lewis M.G. Geleziunas R. Robb M.L. Michael N.L. Barouch D.H. Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat. Commun. 2018 9 1 5429 10.1038/s41467‑018‑07881‑9 30575753
    [Google Scholar]
  8. McMichael A.J. Borrow P. Tomaras G.D. Goonetilleke N. Haynes B.F. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat. Rev. Immunol. 2010 10 1 11 23 10.1038/nri2674 20010788
    [Google Scholar]
  9. Moss W.J. Griffin D.E. Global measles elimination. Nat. Rev. Microbiol. 2006 4 12 900 908 10.1038/nrmicro1550 17088933
    [Google Scholar]
  10. Krause P.R. Klinman D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J. Pediatr. 1995 127 4 518 525 10.1016/S0022‑3476(95)70106‑0 7562270
    [Google Scholar]
  11. Hepburn M.J. Kortepeter M.G. Pittman P.R. Boudreau E.F. Mangiafico J.A. Buck P.A. Norris S.L. Anderson E.L. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 2006 24 15 2843 2849 10.1016/j.vaccine.2005.12.055 16494976
    [Google Scholar]
  12. Cox A.L. Challenges and promise of a hepatitis C virus vaccine. Cold Spring Harb. Perspect. Med. 2020 10 2 a036947 10.1101/cshperspect.a036947 31548228
    [Google Scholar]
  13. Brander C. Frahm N. Walker B.D. The challenges of host and viral diversity in HIV vaccine design. Curr. Opin. Immunol. 2006 18 4 430 437 10.1016/j.coi.2006.05.012 16777397
    [Google Scholar]
  14. Hensley S.E. Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr. Opin. Virol. 2014 8 85 89 10.1016/j.coviro.2014.07.007 25108824
    [Google Scholar]
  15. Alouane T. Laamarti M. Essabbar A. Hakmi M. Bouricha E.M. Chemao-Elfihri M.W. Kartti S. Boumajdi N. Bendani H. Laamarti R. Ghrifi F. Allam L. Aanniz T. Ouadghiri M. El Hafidi N. El Jaoudi R. Benrahma H. Attar J.E. Mentag R. Sbabou L. Nejjari C. Amzazi S. Belyamani L. Ibrahimi A. Genomic diversity and hotspot mutations in 30,983 SARS-CoV-2 genomes: moving toward a universal vaccine for the “confined virus”? Pathogens 2020 9 10 829 10.3390/pathogens9100829 33050463
    [Google Scholar]
  16. Derking R. Sanders R.W. Structure‐guided envelope trimer design in HIV‐1 vaccine development: A narrative review. J. Int. AIDS Soc. 2021 24 S7 e25797 Suppl. 7 10.1002/jia2.25797 34806305
    [Google Scholar]
  17. Gelderblom H.R. Hausmann E.H.S. Özel M. Pauli G. Koch M.A. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 1987 156 1 171 176 10.1016/0042‑6822(87)90449‑1 3643678
    [Google Scholar]
  18. Crispin M. Ward A.B. Wilson I.A. Structure and immune recognition of the HIV glycan shield. Annu. Rev. Biophys. 2018 47 1 499 523 10.1146/annurev‑biophys‑060414‑034156 29595997
    [Google Scholar]
  19. Landais E. Moore P.L. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 2018 15 1 61 10.1186/s12977‑018‑0443‑0 30185183
    [Google Scholar]
  20. Rusert P. Kouyos R.D. Kadelka C. Ebner H. Schanz M. Huber M. Braun D.L. Hozé N. Scherrer A. Magnus C. Weber J. Uhr T. Cippa V. Thorball C.W. Kuster H. Cavassini M. Bernasconi E. Hoffmann M. Calmy A. Battegay M. Rauch A. Yerly S. Aubert V. Klimkait T. Böni J. Fellay J. Regoes R.R. Günthard H.F. Trkola A. Bucher H.C. Ciuffi A. Dollenmaier G. Egger M. Elzi L. Fehr J. Furrer H. Fux C.A. Haerry D. Hasse B. Hirsch H.H. Hösli I. Kahlert C. Kaiser L. Keiser O. Kovari H. Ledergerber B. Martinetti G. de Tejada B.M. Marzolini C. Metzner K.J. Müller N. Nicca D. Pantaleo G. Paioni P. Rudin C. Schmid P. Speck R. Stöckle M. Tarr P. Vernazza P. Wandeler G. Weber R. Swiss HIV Cohort Study Determinants of HIV-1 broadly neutralizing antibody induction. Nat. Med. 2016 22 11 1260 1267 10.1038/nm.4187 27668936
    [Google Scholar]
  21. Rerks-Ngarm S. Pitisuttithum P. Nitayaphan S. Kaewkungwal J. Chiu J. Paris R. Premsri N. Namwat C. de Souza M. Adams E. Benenson M. Gurunathan S. Tartaglia J. McNeil J.G. Francis D.P. Stablein D. Birx D.L. Chunsuttiwat S. Khamboonruang C. Thongcharoen P. Robb M.L. Michael N.L. Kunasol P. Kim J.H. MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009 361 23 2209 2220 10.1056/NEJMoa0908492 19843557
    [Google Scholar]
  22. Johnson JJ Johnson and global partners announce results from phase 2b imbokodo hiv vaccine clinical trial in young women in Sub-Saharan Africa. 2021 Available from: https://www.jnj.com/media-center/press-releases/johnson-johnson-and-global-partners-announce-results-from-phase-2b-imbokodo-hiv-vaccine-clinical-trial-in-young-women-in-sub-saharan-africa
  23. Abbott R.K. Lee J.H. Menis S. Skog P. Rossi M. Ota T. Kulp D.W. Bhullar D. Kalyuzhniy O. Havenar-Daughton C. Schief W.R. Nemazee D. Crotty S. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity 2018 48 1 133 146.e6 10.1016/j.immuni.2017.11.023 29287996
    [Google Scholar]
  24. Ward A.B. Wilson I.A. The HIV ‐1 envelope glycoprotein structure: Nailing down a moving target. Immunol. Rev. 2017 275 1 21 32 10.1111/imr.12507 28133813
    [Google Scholar]
  25. Yasmeen A. Ringe R. Derking R. Cupo A. Julien J.P. Burton D.R. Ward A.B. Wilson I.A. Sanders R.W. Moore J.P. Klasse P.J. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 2014 11 1 41 10.1186/1742‑4690‑11‑41 24884783
    [Google Scholar]
  26. Kulp D.W. Steichen J.M. Pauthner M. Hu X. Schiffner T. Liguori A. Cottrell C.A. Havenar-Daughton C. Ozorowski G. Georgeson E. Kalyuzhniy O. Willis J.R. Kubitz M. Adachi Y. Reiss S.M. Shin M. de Val N. Ward A.B. Crotty S. Burton D.R. Schief W.R. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat. Commun. 2017 8 1 1655 10.1038/s41467‑017‑01549‑6 29162799
    [Google Scholar]
  27. Griffith S.A. McCoy L.E. To bnAb or not to bnAb: Defining broadly neutralising antibodies against HIV-1. Front. Immunol. 2021 12 708227 10.3389/fimmu.2021.708227 34737737
    [Google Scholar]
  28. Barbas C.F. III Björling E. Chiodi F. Dunlop N. Cababa D. Jones T.M. Zebedee S.L. Persson M.A. Nara P.L. Norrby E. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 1992 89 19 9339 9343 10.1073/pnas.89.19.9339 1384050
    [Google Scholar]
  29. Walker L.M. Phogat S.K. Chan-Hui P.Y. Wagner D. Phung P. Goss J.L. Wrin T. Simek M.D. Fling S. Mitcham J.L. Lehrman J.K. Priddy F.H. Olsen O.A. Frey S.M. Hammond P.W. Kaminsky S. Zamb T. Moyle M. Koff W.C. Poignard P. Burton D.R. Protocol G Principal Investigators Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009 326 5950 285 289 10.1126/science.1178746 19729618
    [Google Scholar]
  30. Balla-Jhagjhoorsingh S.S. Corti D. Heyndrickx L. Willems E. Vereecken K. Davis D. Vanham G. The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. PLoS One 2013 8 7 e68863 10.1371/journal.pone.0068863 23874792
    [Google Scholar]
  31. Zhou T. Georgiev I. Wu X. Yang Z.Y. Dai K. Finzi A. Do Kwon Y. Scheid J.F. Shi W. Xu L. Yang Y. Zhu J. Nussenzweig M.C. Sodroski J. Shapiro L. Nabel G.J. Mascola J.R. Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010 329 5993 811 817 10.1126/science.1192819 20616231
    [Google Scholar]
  32. Trkola A. Purtscher M. Muster T. Ballaun C. Buchacher A. Sullivan N. Srinivasan K. Sodroski J. Moore J.P. Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996 70 2 1100 1108 10.1128/jvi.70.2.1100‑1108.1996 8551569
    [Google Scholar]
  33. Muster T. Steindl F. Purtscher M. Trkola A. Klima A. Himmler G. Rüker F. Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993 67 11 6642 6647 10.1128/jvi.67.11.6642‑6647.1993 7692082
    [Google Scholar]
  34. Buchacher A. Predl R. Strutzenberger K. Steinfellner W. Trkola A. Purtscher M. Gruber G. Tauer C. Steindl F. Jungbauer A. Katinger H. Generation of human monoclonal antibodies against HIV-1 proteins; Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 1994 10 4 359 369 10.1089/aid.1994.10.359 7520721
    [Google Scholar]
  35. Escolano A. Dosenovic P. Nussenzweig M.C. Progress toward active or passive HIV-1 vaccination. J. Exp. Med. 2017 214 1 3 16 10.1084/jem.20161765 28003309
    [Google Scholar]
  36. Kwong P.D. Mascola J.R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 2018 48 5 855 871 10.1016/j.immuni.2018.04.029 29768174
    [Google Scholar]
  37. Burton D.R. Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 2016 34 1 635 659 10.1146/annurev‑immunol‑041015‑055515 27168247
    [Google Scholar]
  38. McCoy L.E. Burton D.R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 2017 275 1 11 20 10.1111/imr.12484 28133814
    [Google Scholar]
  39. Subbaraman H. Schanz M. Trkola A. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Retrovirology 2018 15 1 52 10.1186/s12977‑018‑0433‑2 30055627
    [Google Scholar]
  40. Sok D. Burton D.R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 2018 19 11 1179 1188 10.1038/s41590‑018‑0235‑7 30333615
    [Google Scholar]
  41. Lee J.H. Leaman D.P. Kim A.S. Torrents de la Peña A. Sliepen K. Yasmeen A. Derking R. Ramos A. de Taeye S.W. Ozorowski G. Klein F. Burton D.R. Nussenzweig M.C. Poignard P. Moore J.P. Klasse P.J. Sanders R.W. Zwick M.B. Wilson I.A. Ward A.B. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat. Commun. 2015 6 1 8167 10.1038/ncomms9167 26404402
    [Google Scholar]
  42. Kunert R. Rüker F. Katinger H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: Identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retroviruses 1998 14 13 1115 1128 10.1089/aid.1998.14.1115 9737583
    [Google Scholar]
  43. Kunert R. Wolbank S. Stiegler G. Weik R. Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res. Hum. Retroviruses 2004 20 7 755 762 10.1089/0889222041524571 15307922
    [Google Scholar]
  44. Yoon H. Macke J. West A.P. Jr Foley B. Bjorkman P.J. Korber B. Yusim K. CATNAP: A tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 2015 43 W1 W213 W219 10.1093/nar/gkv404 26044712
    [Google Scholar]
  45. Giudicelli V. Chaume D. Lefranc M.P. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res. 2004 32 Web Server Suppl. 2 W435 W440 10.1093/nar/gkh412 15215425
    [Google Scholar]
  46. van den Berg F.T. Makoah N.A. Ali S.A. Scott T.A. Mapengo R.E. Mutsvunguma L.Z. Mkhize N.N. Lambson B.E. Kgagudi P.D. Crowther C. Abdool Karim S.S. Balazs A.B. Weinberg M.S. Ely A. Arbuthnot P.B. Morris L. AAV-mediated expression of broadly neutralizing and vaccine-like antibodies targeting the HIV-1 envelope V2 region. Mol. Ther. Methods Clin. Dev. 2019 14 100 112 10.1016/j.omtm.2019.06.002 31334303
    [Google Scholar]
  47. Pegu A. Hessell A.J. Mascola J.R. Haigwood N.L. Use of broadly neutralizing antibodies for HIV ‐1 prevention. Immunol. Rev. 2017 275 1 296 312 10.1111/imr.12511 28133803
    [Google Scholar]
  48. Gautam R. Nishimura Y. Gaughan N. Gazumyan A. Schoofs T. Buckler-White A. Seaman M.S. Swihart B.J. Follmann D.A. Nussenzweig M.C. Martin M.A. A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection. Nat. Med. 2018 24 5 610 616 10.1038/s41591‑018‑0001‑2 29662199
    [Google Scholar]
  49. Moldt B. Rakasz E.G. Schultz N. Chan-Hui P.Y. Swiderek K. Weisgrau K.L. Piaskowski S.M. Bergman Z. Watkins D.I. Poignard P. Burton D.R. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 2012 109 46 18921 18925 10.1073/pnas.1214785109 23100539
    [Google Scholar]
  50. van Gils M.J. Sanders R.W. In vivo protection by broadly neutralizing HIV antibodies. Trends Microbiol. 2014 22 10 550 551 10.1016/j.tim.2014.08.006 25169020
    [Google Scholar]
  51. Hessell A.J. Haigwood N.L. Animal models in HIV-1 protection and therapy. Curr. Opin. HIV AIDS 2015 10 3 170 176 10.1097/COH.0000000000000152 25730345
    [Google Scholar]
  52. Balazs A.B. Ouyang Y. Hong C.M. Chen J. Nguyen S.M. Rao D.S. An D.S. Baltimore D. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 2014 20 3 296 300 10.1038/nm.3471 24509526
    [Google Scholar]
  53. Hahn P.A. Martins M.A. Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection. J. Virus Erad. 2023 9 1 100316 10.1016/j.jve.2023.100316 36915910
    [Google Scholar]
  54. Burton D.R. Advancing an HIV vaccine; Advancing vaccinology. Nat. Rev. Immunol. 2019 19 2 77 78 10.1038/s41577‑018‑0103‑6 30560910
    [Google Scholar]
  55. Burton D.R. Ahmed R. Barouch D.H. Butera S.T. Crotty S. Godzik A. Kaufmann D.E. McElrath M.J. Nussenzweig M.C. Pulendran B. Scanlan C.N. Schief W.R. Silvestri G. Streeck H. Walker B.D. Walker L.M. Ward A.B. Wilson I.A. Wyatt R. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012 12 4 396 407 10.1016/j.chom.2012.09.008 23084910
    [Google Scholar]
  56. Haynes B.F. Kelsoe G. Harrison S.C. Kepler T.B. B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012 30 5 423 433 10.1038/nbt.2197 22565972
    [Google Scholar]
  57. Haynes B.F. Shaw G.M. Korber B. Kelsoe G. Sodroski J. Hahn B.H. Borrow P. McMichael A.J. HIV-host interactions: Implications for vaccine design. Cell Host Microbe 2016 19 3 292 303 10.1016/j.chom.2016.02.002 26922989
    [Google Scholar]
  58. Walker L.M. Huber M. Doores K.J. Falkowska E. Pejchal R. Julien J.P. Wang S.K. Ramos A. Chan-Hui P.Y. Moyle M. Mitcham J.L. Hammond P.W. Olsen O.A. Phung P. Fling S. Wong C.H. Phogat S. Wrin T. Simek M.D. Principal Investigators P.G. Koff W.C. Wilson I.A. Burton D.R. Poignard P. Protocol G Principal Investigators Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 477 7365 466 470 10.1038/nature10373 21849977
    [Google Scholar]
  59. Bonsignori M. Hwang K.K. Chen X. Tsao C.Y. Morris L. Gray E. Marshall D.J. Crump J.A. Kapiga S.H. Sam N.E. Sinangil F. Pancera M. Yongping Y. Zhang B. Zhu J. Kwong P.D. O’Dell S. Mascola J.R. Wu L. Nabel G.J. Phogat S. Seaman M.S. Whitesides J.F. Moody M.A. Kelsoe G. Yang X. Sodroski J. Shaw G.M. Montefiori D.C. Kepler T.B. Tomaras G.D. Alam S.M. Liao H.X. Haynes B.F. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011 85 19 9998 10009 10.1128/JVI.05045‑11 21795340
    [Google Scholar]
  60. Wu X. Zhou T. Zhu J. Zhang B. Georgiev I. Wang C. Chen X. Longo N.S. Louder M. McKee K. O’Dell S. Perfetto S. Schmidt S.D. Shi W. Wu L. Yang Y. Yang Z.Y. Yang Z. Zhang Z. Bonsignori M. Crump J.A. Kapiga S.H. Sam N.E. Haynes B.F. Simek M. Burton D.R. Koff W.C. Doria-Rose N.A. Connors M. Mullikin J.C. Nabel G.J. Roederer M. Shapiro L. Kwong P.D. Mascola J.R. NISC Comparative Sequencing Program Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011 333 6049 1593 1602 10.1126/science.1207532 21835983
    [Google Scholar]
  61. Ajibola G. Masheto G. Shapiro R. Antibody interventions in HIV: Broadly neutralizing mAbs in children. Curr. Opin. HIV AIDS 2023 18 4 217 224 10.1097/COH.0000000000000806 37278286
    [Google Scholar]
  62. Kumar S. Bajpai P. Joyce C. Kabra S.K. Lodha R. Burton D.R. Briney B. Luthra K. B cell repertoire sequencing of HIV-1 pediatric elite-neutralizers identifies multiple broadly neutralizing antibody clonotypes. Front. Immunol. 2024 15 1272493 10.3389/fimmu.2024.1272493 38433846
    [Google Scholar]
  63. Simonich C.A. Williams K.L. Verkerke H.P. Williams J.A. Nduati R. Lee K.K. Overbaugh J. HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 2016 166 1 77 87 10.1016/j.cell.2016.05.055 27345369
    [Google Scholar]
  64. Mascola J.R. Haynes B.F. HIV ‐1 neutralizing antibodies: Understanding nature’s pathways. Immunol. Rev. 2013 254 1 225 244 10.1111/imr.12075 23772623
    [Google Scholar]
  65. Alam S.M. Aussedat B. Vohra Y. Meyerhoff R.R. Cale E.M. Walkowicz W.E. Radakovich N.A. Anasti K. Armand L. Parks R. Sutherland L. Scearce R. Joyce M.G. Pancera M. Druz A. Georgiev I.S. Von Holle T. Eaton A. Fox C. Reed S.G. Louder M. Bailer R.T. Morris L. Abdool-Karim S.S. Cohen M. Liao H.X. Montefiori D.C. Park P.K. Fernández-Tejada A. Wiehe K. Santra S. Kepler T.B. Saunders K.O. Sodroski J. Kwong P.D. Mascola J.R. Bonsignori M. Moody M.A. Danishefsky S. Haynes B.F. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci. Transl. Med. 2017 9 381 eaai7521 10.1126/scitranslmed.aai7521 28298421
    [Google Scholar]
  66. Freund N.T. Wang H. Scharf L. Nogueira L. Horwitz J.A. Bar-On Y. Golijanin J. Sievers S.A. Sok D. Cai H. Cesar Lorenzi J.C. Halper-Stromberg A. Toth I. Piechocka-Trocha A. Gristick H.B. van Gils M.J. Sanders R.W. Wang L.X. Seaman M.S. Burton D.R. Gazumyan A. Walker B.D. West A.P. Jr Bjorkman P.J. Nussenzweig M.C. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci. Transl. Med. 2017 9 373 eaal2144 10.1126/scitranslmed.aal2144 28100831
    [Google Scholar]
  67. Mouquet H. Scharf L. Euler Z. Liu Y. Eden C. Scheid J.F. Halper-Stromberg A. Gnanapragasam P.N.P. Spencer D.I.R. Seaman M.S. Schuitemaker H. Feizi T. Nussenzweig M.C. Bjorkman P.J. Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 2012 109 47 E3268 E3277 10.1073/pnas.1217207109 23115339
    [Google Scholar]
  68. MacLeod D.T. Choi N.M. Briney B. Garces F. Ver L.S. Landais E. Murrell B. Wrin T. Kilembe W. Liang C.H. Ramos A. Bian C.B. Wickramasinghe L. Kong L. Eren K. Wu C.Y. Wong C.H. Price M.A. Gilmour J. Fast P. Kamali A. Sanders E.J. Anzala O. Allen S. Hunter E. Karita E. Kilembe W. Lakhi S. Inambao M. Edward V. Bekker L-G. Kosakovsky Pond S.L. Wilson I.A. Burton D.R. Poignard P. IAVI Protocol C Investigators & The IAVI African HIV Research Network Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch. Immunity 2016 44 5 1215 1226 10.1016/j.immuni.2016.04.016 27192579
    [Google Scholar]
  69. Finney J. Kelsoe G. Poly- and autoreactivity of HIV-1 bNAbs: Implications for vaccine design. Retrovirology 2018 15 1 53 10.1186/s12977‑018‑0435‑0 30055635
    [Google Scholar]
  70. Verkoczy L. Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies. Curr. Opin. HIV AIDS 2014 9 3 224 234 10.1097/COH.0000000000000049 24714565
    [Google Scholar]
  71. Sanders R.W. Derking R. Cupo A. Julien J.P. Yasmeen A. de Val N. Kim H.J. Blattner C. de la Peña A.T. Korzun J. Golabek M. de los Reyes K. Ketas T.J. van Gils M.J. King C.R. Wilson I.A. Ward A.B. Klasse P.J. Moore J.P. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013 9 9 e1003618 10.1371/journal.ppat.1003618 24068931
    [Google Scholar]
  72. Klasse P.J. Ketas T.J. Cottrell C.A. Ozorowski G. Debnath G. Camara D. Francomano E. Pugach P. Ringe R.P. LaBranche C.C. van Gils M.J. Bricault C.A. Barouch D.H. Crotty S. Silvestri G. Kasturi S. Pulendran B. Wilson I.A. Montefiori D.C. Sanders R.W. Ward A.B. Moore J.P. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS Pathog. 2018 14 2 e1006913 10.1371/journal.ppat.1006913 29474444
    [Google Scholar]
  73. de Taeye S.W. Ozorowski G. Torrents de la Peña A. Guttman M. Julien J.P. van den Kerkhof T.L.G.M. Burger J.A. Pritchard L.K. Pugach P. Yasmeen A. Crampton J. Hu J. Bontjer I. Torres J.L. Arendt H. DeStefano J. Koff W.C. Schuitemaker H. Eggink D. Berkhout B. Dean H. LaBranche C. Crotty S. Crispin M. Montefiori D.C. Klasse P.J. Lee K.K. Moore J.P. Wilson I.A. Ward A.B. Sanders R.W. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 2015 163 7 1702 1715 10.1016/j.cell.2015.11.056 26687358
    [Google Scholar]
  74. Torrents de la Peña A. Julien J.P. de Taeye S.W. Garces F. Guttman M. Ozorowski G. Pritchard L.K. Behrens A.J. Go E.P. Burger J.A. Schermer E.E. Sliepen K. Ketas T.J. Pugach P. Yasmeen A. Cottrell C.A. Torres J.L. Vavourakis C.D. van Gils M.J. LaBranche C. Montefiori D.C. Desaire H. Crispin M. Klasse P.J. Lee K.K. Moore J.P. Ward A.B. Wilson I.A. Sanders R.W. Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization. Cell Rep. 2017 20 8 1805 1817 10.1016/j.celrep.2017.07.077 28834745
    [Google Scholar]
  75. Joyce M.G. Georgiev I.S. Yang Y. Druz A. Geng H. Chuang G.Y. Kwon Y.D. Pancera M. Rawi R. Sastry M. Stewart-Jones G.B.E. Zheng A. Zhou T. Choe M. Van Galen J.G. Chen R.E. Lees C.R. Narpala S. Chambers M. Tsybovsky Y. Baxa U. McDermott A.B. Mascola J.R. Kwong P.D. Soluble prefusion closed DS-SOSIP. 664-Env trimers of diverse HIV-1 strains. Cell Rep. 2017 21 10 2992 3002 10.1016/j.celrep.2017.11.016 29212041
    [Google Scholar]
  76. Rutten L. Lai Y.T. Blokland S. Truan D. Bisschop I.J.M. Strokappe N.M. Koornneef A. van Manen D. Chuang G.Y. Farney S.K. Schuitemaker H. Kwong P.D. Langedijk J.P.M. A universal approach to optimize the folding and stability of prefusion-closed HIV-1 envelope trimers. Cell Rep. 2018 23 2 584 595 10.1016/j.celrep.2018.03.061 29642014
    [Google Scholar]
  77. Klasse P.J. LaBranche C.C. Ketas T.J. Ozorowski G. Cupo A. Pugach P. Ringe R.P. Golabek M. van Gils M.J. Guttman M. Lee K.K. Wilson I.A. Butera S.T. Ward A.B. Montefiori D.C. Sanders R.W. Moore J.P. Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP. 664 trimers from clades A, B and C. PLoS Pathog. 2016 12 9 e1005864 10.1371/journal.ppat.1005864 27627672
    [Google Scholar]
  78. Torrents de la Peña A. de Taeye S.W. Sliepen K. LaBranche C.C. Burger J.A. Schermer E.E. Montefiori D.C. Moore J.P. Klasse P.J. Sanders R.W. Immunogenicity in rabbits of HIV-1 SOSIP trimers from clades A, B, and C, given individually, sequentially, or in combination. J. Virol. 2018 92 8 01957 17 10.1128/jvi 29367243
    [Google Scholar]
  79. Brinkkemper M. Kerster G. Brouwer P.J.M. Tran A.S. Torres J.L. Ettema R.A. Nijhuis H. Allen J.D. Zhu W. Gao H. Lee W.H. Bijl T.P.L. Snitselaar J.L. Burger J.A. Bontjer I. Olijhoek W. Ravichandran R. van Breemen M.J. Del Moral-Sánchez I. Derking R. Sliepen K. Ozorowski G. Crispin M. Montefiori D.C. Claireaux M. Ward A.B. van Gils M.J. King N.P. Sanders R.W. Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLoS Pathog. 2024 20 10 e1012558 10.1371/journal.ppat.1012558 39361585
    [Google Scholar]
  80. Cohen K.W. Fiore-Gartland A. Walsh S.R. Yusim K. Frahm N. Elizaga M.L. Maenza J. Scott H. Mayer K.H. Goepfert P.A. Edupuganti S. Pantaleo G. Hutter J. Morris D.E. De Rosa S.C. Geraghty D.E. Robb M.L. Michael N.L. Fischer W. Giorgi E.E. Malhi H. Pensiero M.N. Ferrari G. Tomaras G.D. Montefiori D.C. Gilbert P.B. McElrath M.J. Haynes B.F. Korber B.T. Baden L.R. NIAID HVTN 106 Study Group Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. J. Clin. Invest. 2023 133 4 e163338 10.1172/JCI163338 36787249
    [Google Scholar]
  81. Brouwer P.J.M. Antanasijevic A. de Gast M. Allen J.D. Bijl T.P.L. Yasmeen A. Ravichandran R. Burger J.A. Ozorowski G. Torres J.L. LaBranche C. Montefiori D.C. Ringe R.P. van Gils M.J. Moore J.P. Klasse P.J. Crispin M. King N.P. Ward A.B. Sanders R.W. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ Vaccines 2021 6 1 24 10.1038/s41541‑021‑00285‑9 33563983
    [Google Scholar]
  82. McCoy L.E. van Gils M.J. Ozorowski G. Messmer T. Briney B. Voss J.E. Kulp D.W. Macauley M.S. Sok D. Pauthner M. Menis S. Cottrell C.A. Torres J.L. Hsueh J. Schief W.R. Wilson I.A. Ward A.B. Sanders R.W. Burton D.R. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies. Cell Rep. 2016 16 9 2327 2338 10.1016/j.celrep.2016.07.074 27545891
    [Google Scholar]
  83. Murji A.A. Qin J.S. Hermanus T. Morris L. Georgiev I.S. Elicitation of neutralizing antibody responses to HIV-1 immunization with nanoparticle vaccine platforms. Viruses 2021 13 7 1296 10.3390/v13071296 34372503
    [Google Scholar]
  84. Guenaga J. Alirezaei M. Feng Y. Alameh M.G. Lee W.H. Baboo S. Cluff J. Wilson R. Bale S. Ozorowski G. Lin P. Tam Y. Diedrich J.K. Yates J.R. III Paulson J.C. Ward A.B. Weissman D. Wyatt R.T. mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies. Front. Immunol. 2024 15 1426232 10.3389/fimmu.2024.1426232 39119336
    [Google Scholar]
  85. Aldon Y. McKay P.F. Allen J. Ozorowski G. Felfödiné Lévai R. Tolazzi M. Rogers P. He L. de Val N. Fábián K. Scarlatti G. Zhu J. Ward A.B. Crispin M. Shattock R.J. Rational design of DNA-expressed stabilized native-like HIV-1 envelope trimers. Cell Rep. 2018 24 12 3324 3338.e5 10.1016/j.celrep.2018.08.051 30232012
    [Google Scholar]
  86. Sugimoto C. Nakayama E.E. Shioda T. Villinger F. Ansari A.A. Yamamoto N. Suzuki Y. Nagai Y. Mori K. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: Induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant. J. Gen. Virol. 2008 89 2 554 566 10.1099/vir.0.83186‑0 18198387
    [Google Scholar]
  87. Schorcht A. Cottrell C.A. Pugach P. Ringe R.P. Han A.X. Allen J.D. van den Kerkhof T.L.G.M. Seabright G.E. Schermer E.E. Ketas T.J. Burger J.A. van Schooten J. LaBranche C.C. Ozorowski G. de Val N. Bader D.L.V. Schuitemaker H. Russell C.A. Montefiori D.C. van Gils M.J. Crispin M. Klasse P.J. Ward A.B. Moore J.P. Sanders R.W. The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization. J. Virol. 2022 96 1 e01552-21 10.1128/JVI.01552‑21 34669426
    [Google Scholar]
  88. Nelson A.N. Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques. bioRxiv 2023
    [Google Scholar]
  89. Dingens A.S. Pratap P. Malone K. Hilton S.K. Ketas T. Cottrell C.A. Overbaugh J. Moore J.P. Klasse P.J. Ward A.B. Bloom J.D. High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. eLife 2021 10 e64281 10.7554/eLife.64281 33438580
    [Google Scholar]
  90. Kumar R. Deshpande S. Sewall L.M. Ozorowski G. Cottrell C.A. Lee W.H. Holden L.G. Richey S.T. Chandrawacar A.S. Dhiman K. Ashish Kumar V. Ahmed S. Hingankar N. Kumar N. Murugavel K.G. Srikrishnan A.K. Sok D. Ward A.B. Bhattacharya J. Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer. PLoS Pathog. 2021 17 4 e1008977 10.1371/journal.ppat.1008977 33826683
    [Google Scholar]
  91. Sanders R.W. van Gils M.J. Derking R. Sok D. Ketas T.J. Burger J.A. Ozorowski G. Cupo A. Simonich C. Goo L. Arendt H. Kim H.J. Lee J.H. Pugach P. Williams M. Debnath G. Moldt B. van Breemen M.J. Isik G. Medina-Ramírez M. Back J.W. Koff W.C. Julien J.P. Rakasz E.G. Seaman M.S. Guttman M. Lee K.K. Klasse P.J. LaBranche C. Schief W.R. Wilson I.A. Overbaugh J. Burton D.R. Ward A.B. Montefiori D.C. Dean H. Moore J.P. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015 349 6244 aac4223 10.1126/science.aac4223 26089353
    [Google Scholar]
  92. Hu J.K. Crampton J.C. Cupo A. Ketas T. van Gils M.J. Sliepen K. de Taeye S.W. Sok D. Ozorowski G. Deresa I. Stanfield R. Ward A.B. Burton D.R. Klasse P.J. Sanders R.W. Moore J.P. Crotty S. Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J. Virol. 2015 89 20 10383 10398 10.1128/JVI.01653‑15 26246566
    [Google Scholar]
  93. Haynes B.F. Wiehe K. Borrow P. Saunders K.O. Korber B. Wagh K. McMichael A.J. Kelsoe G. Hahn B.H. Alt F. Shaw G.M. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023 23 3 142 158 10.1038/s41577‑022‑00753‑w 35962033
    [Google Scholar]
  94. Kim J. Vasan S. Kim J.H. Ake J.A. Current approaches to HIV vaccine development: A narrative review. J. Int. AIDS Soc. 2021 24 S7 e25793 Suppl. 7 10.1002/jia2.25793 34806296
    [Google Scholar]
  95. Ratnapriya S. Perez-Greene E. Schifanella L. Herschhorn A. Adjuvant‐mediated enhancement of the immune response to HIV vaccines. FEBS J. 2022 289 12 3317 3334 10.1111/febs.15814 33705608
    [Google Scholar]
  96. Brinkkemper M. Sliepen K. Nanoparticle vaccines for inducing HIV-1 neutralizing antibodies. Vaccines 2019 7 3 76 10.3390/vaccines7030076 31362378
    [Google Scholar]
  97. Mu Z. Haynes B.F. Cain D.W. HIV mRNA vaccines—progress and future paths. Vaccines 2021 9 2 134 10.3390/vaccines9020134 33562203
    [Google Scholar]
  98. Kwong P.D. Mascola J.R. Nabel G.J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat. Rev. Immunol. 2013 13 9 693 701 10.1038/nri3516 23969737
    [Google Scholar]
  99. Cottrell C.A. Focusing antibody responses to the fusion peptide in rhesus macaques. bioRxiv 2023
    [Google Scholar]
  100. Bhagchandani S.H. Yang L. Lam J.H. Maiorino L. Ben-Akiva E. Rodrigues K.A. Romanov A. Suh H. Aung A. Wu S. Wadhera A. Chakraborty A.K. Irvine D.J. Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response. Sci. Immunol. 2024 9 99 eadl3755 10.1126/sciimmunol.adl3755 39303017
    [Google Scholar]
  101. Yousefpour P. Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP. bioRxiv 2024 2024.08
    [Google Scholar]
  102. Rodrigues K.A. Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion. bioRxiv 2024
    [Google Scholar]
  103. Ramezani-Rad P. Dose-dependent regulation of immune memory responses against HIV by saponin monophosphoryl lipid A nanoparticle adjuvant. bioRxiv 2024 2024.07
    [Google Scholar]
  104. Rodrigues K.A. Optimization of an alum-anchored clinical HIV vaccine candidate. . NPJ. Vaccines 2023 8 1 117 10.3390/vaccines11010117 36679963
    [Google Scholar]
  105. Houser K.V. Gaudinski M.R. Happe M. Narpala S. Verardi R. Sarfo E.K. Corrigan A.R. Wu R. Rothwell R.S. Novik L. Hendel C.S. Gordon I.J. Berkowitz N.M. Cartagena C.T. Widge A.T. Coates E.E. Strom L. Hickman S. Conan-Cibotti M. Vazquez S. Trofymenko O. Plummer S. Stein J. Case C.L. Nason M. Biju A. Parchment D.K. Changela A. Cheng C. Duan H. Geng H. Teng I.T. Zhou T. O’Connell S. Barry C. Carlton K. Gall J.G. Flach B. Doria-Rose N.A. Graham B.S. Koup R.A. McDermott A.B. Mascola J.R. Kwong P.D. Ledgerwood J.E. VRC 018 Study Team Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine 2022 48 101477 10.1016/j.eclinm.2022.101477 35783486
    [Google Scholar]
  106. Hahn W.O. Parks K.R. Shen M. Ozorowski G. Janes H. Ballweber-Fleming L. Woodward Davis A.S. Duplessis C. Tomai M. Dey A.K. Sagawa Z.K. De Rosa S.C. Seese A. Kallur Siddaramaiah L. Stamatatos L. Lee W.H. Sewall L.M. Karlinsey D. Turner H.L. Rubin V. Furth S. MacPhee K. Duff M. Corey L. Keefer M.C. Edupuganti S. Frank I. Maenza J. Baden L.R. Hyrien O. Sanders R.W. Moore J.P. Ward A.B. Tomaras G.D. Montefiori D.C. Rouphael N. McElrath M.J. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. J. Exp. Med. 2024 221 10 e20240604 10.1084/jem.20240604 39235529
    [Google Scholar]
  107. Reiss E.I.M.M. van Haaren M.M. van Schooten J. Claireaux M.A.F. Maisonnasse P. Antanasijevic A. Allen J.D. Bontjer I. Torres J.L. Lee W-H. Ozorowski G. Vázquez Bernat N. Kaduk M. Aldon Y. Burger J.A. Chawla H. Aartse A. Tolazzi M. Gao H. Mundsperger P. Crispin M. Montefiori D.C. Karlsson Hedestam G.B. Scarlatti G. Ward A.B. Le Grand R. Shattock R. Dereuddre-Bosquet N. Sanders R.W. van Gils M.J. Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. NPJ Vaccines 2022 7 1 152 10.1038/s41541‑022‑00576‑9 36433972
    [Google Scholar]
  108. van Schooten J. van Haaren M.M. Li H. McCoy L.E. Havenar-Daughton C. Cottrell C.A. Burger J.A. van der Woude P. Helgers L.C. Tomris I. Labranche C.C. Montefiori D.C. Ward A.B. Burton D.R. Moore J.P. Sanders R.W. Crotty S. Shaw G.M. van Gils M.J. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS Pathog. 2021 17 8 e1009736 10.1371/journal.ppat.1009736 34432859
    [Google Scholar]
  109. Bianchi M. Turner H.L. Nogal B. Cottrell C.A. Oyen D. Pauthner M. Bastidas R. Nedellec R. McCoy L.E. Wilson I.A. Burton D.R. Ward A.B. Hangartner L. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity 2018 49 2 288 300.e8 10.1016/j.immuni.2018.07.009 30097292
    [Google Scholar]
  110. Steichen J.M. Lin Y.C. Havenar-Daughton C. Pecetta S. Ozorowski G. Willis J.R. Toy L. Sok D. Liguori A. Kratochvil S. Torres J.L. Kalyuzhniy O. Melzi E. Kulp D.W. Raemisch S. Hu X. Bernard S.M. Georgeson E. Phelps N. Adachi Y. Kubitz M. Landais E. Umotoy J. Robinson A. Briney B. Wilson I.A. Burton D.R. Ward A.B. Crotty S. Batista F.D. Schief W.R. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science 2019 366 6470 eaax4380 10.1126/science.aax4380 31672916
    [Google Scholar]
  111. Jardine J.G. Kulp D.W. Havenar-Daughton C. Sarkar A. Briney B. Sok D. Sesterhenn F. Ereño-Orbea J. Kalyuzhniy O. Deresa I. Hu X. Spencer S. Jones M. Georgeson E. Adachi Y. Kubitz M. deCamp A.C. Julien J.P. Wilson I.A. Burton D.R. Crotty S. Schief W.R. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 2016 351 6280 1458 1463 10.1126/science.aad9195 27013733
    [Google Scholar]
  112. Stamatatos L. Pancera M. McGuire A.T. Germline‐targeting immunogens. Immunol. Rev. 2017 275 1 203 216 10.1111/imr.12483 28133796
    [Google Scholar]
  113. McGuire A.T. Hoot S. Dreyer A.M. Lippy A. Stuart A. Cohen K.W. Jardine J. Menis S. Scheid J.F. West A.P. Schief W.R. Stamatatos L. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 2013 210 4 655 663 10.1084/jem.20122824 23530120
    [Google Scholar]
  114. Jardine J. Julien J.P. Menis S. Ota T. Kalyuzhniy O. McGuire A. Sok D. Huang P.S. MacPherson S. Jones M. Nieusma T. Mathison J. Baker D. Ward A.B. Burton D.R. Stamatatos L. Nemazee D. Wilson I.A. Schief W.R. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013 340 6133 711 716 10.1126/science.1234150 23539181
    [Google Scholar]
  115. Dosenovic P. von Boehmer L. Escolano A. Jardine J. Freund N.T. Gitlin A.D. McGuire A.T. Kulp D.W. Oliveira T. Scharf L. Pietzsch J. Gray M.D. Cupo A. van Gils M.J. Yao K.H. Liu C. Gazumyan A. Seaman M.S. Björkman P.J. Sanders R.W. Moore J.P. Stamatatos L. Schief W.R. Nussenzweig M.C. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 2015 161 7 1505 1515 10.1016/j.cell.2015.06.003 26091035
    [Google Scholar]
  116. Tian M. Cheng C. Chen X. Duan H. Cheng H.L. Dao M. Sheng Z. Kimble M. Wang L. Lin S. Schmidt S.D. Du Z. Joyce M.G. Chen Y. DeKosky B.J. Chen Y. Normandin E. Cantor E. Chen R.E. Doria-Rose N.A. Zhang Y. Shi W. Kong W.P. Choe M. Henry A.R. Laboune F. Georgiev I.S. Huang P.Y. Jain S. McGuire A.T. Georgeson E. Menis S. Douek D.C. Schief W.R. Stamatatos L. Kwong P.D. Shapiro L. Haynes B.F. Mascola J.R. Alt F.W. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell 2016 166 6 1471 1484.e18 10.1016/j.cell.2016.07.029 27610571
    [Google Scholar]
  117. Huang D. Abbott R.K. Havenar-Daughton C. Skog P.D. Al-Kolla R. Groschel B. Blane T.R. Menis S. Tran J.T. Thinnes T.C. Volpi S.A. Liguori A. Schiffner T. Villegas S.M. Kalyuzhniy O. Pintea M. Voss J.E. Phelps N. Tingle R. Rodriguez A.R. Martin G. Kupryianov S. deCamp A. Schief W.R. Nemazee D. Crotty S. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proc. Natl. Acad. Sci. USA 2020 117 37 22920 22931 10.1073/pnas.2004489117 32873644
    [Google Scholar]
  118. Jardine J.G. Ota T. Sok D. Pauthner M. Kulp D.W. Kalyuzhniy O. Skog P.D. Thinnes T.C. Bhullar D. Briney B. Menis S. Jones M. Kubitz M. Spencer S. Adachi Y. Burton D.R. Schief W.R. Nemazee D. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015 349 6244 156 161 10.1126/science.aac5894 26089355
    [Google Scholar]
  119. Medina-Ramírez M. Garces F. Escolano A. Skog P. de Taeye S.W. Del Moral-Sanchez I. McGuire A.T. Yasmeen A. Behrens A.J. Ozorowski G. van den Kerkhof T.L.G.M. Freund N.T. Dosenovic P. Hua Y. Gitlin A.D. Cupo A. van der Woude P. Golabek M. Sliepen K. Blane T. Kootstra N. van Breemen M.J. Pritchard L.K. Stanfield R.L. Crispin M. Ward A.B. Stamatatos L. Klasse P.J. Moore J.P. Nemazee D. Nussenzweig M.C. Wilson I.A. Sanders R.W. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 2017 214 9 2573 2590 10.1084/jem.20161160 28847869
    [Google Scholar]
  120. Melzi E. Willis J.R. Ma K.M. Lin Y.C. Kratochvil S. Berndsen Z.T. Landais E.A. Kalyuzhniy O. Nair U. Warner J. Steichen J.M. Kalyuzhniy A. Le A. Pecetta S. Perez M. Kirsch K. Weldon S.R. Falcone S. Himansu S. Carfi A. Sok D. Ward A.B. Schief W.R. Batista F.D. Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice. Immunity 2022 55 11 2168 2186.e6 10.1016/j.immuni.2022.09.003 36179690
    [Google Scholar]
  121. Parks K.R. MacCamy A.J. Trichka J. Gray M. Weidle C. Borst A.J. Khechaduri A. Takushi B. Agrawal P. Guenaga J. Wyatt R.T. Coler R. Seaman M. LaBranche C. Montefiori D.C. Veesler D. Pancera M. McGuire A. Stamatatos L. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. Cell Rep. 2019 29 10 3060 3072.e7 10.1016/j.celrep.2019.10.071 31801073
    [Google Scholar]
  122. Sok D. Briney B. Jardine J.G. Kulp D.W. Menis S. Pauthner M. Wood A. Lee E.C. Le K.M. Jones M. Ramos A. Kalyuzhniy O. Adachi Y. Kubitz M. MacPherson S. Bradley A. Friedrich G.A. Schief W.R. Burton D.R. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 2016 353 6307 1557 1560 10.1126/science.aah3945 27608668
    [Google Scholar]
  123. Wang X. Ray R. Kratochvil S. Melzi E. Lin Y.C. Giguere S. Xu L. Warner J. Cheon D. Liguori A. Groschel B. Phelps N. Adachi Y. Tingle R. Wu L. Crotty S. Kirsch K.H. Nair U. Schief W.R. Batista F.D. Multiplexed CRISPR/CAS9‐mediated engineering of pre‐clinical mouse models bearing native human B cell receptors. EMBO J. 2021 40 2 e105926 10.15252/embj.2020105926 33258500
    [Google Scholar]
  124. Escolano A. Gristick H.B. Abernathy M.E. Merkenschlager J. Gautam R. Oliveira T.Y. Pai J. West A.P. Jr Barnes C.O. Cohen A.A. Wang H. Golijanin J. Yost D. Keeffe J.R. Wang Z. Zhao P. Yao K.H. Bauer J. Nogueira L. Gao H. Voll A.V. Montefiori D.C. Seaman M.S. Gazumyan A. Silva M. McGuire A.T. Stamatatos L. Irvine D.J. Wells L. Martin M.A. Bjorkman P.J. Nussenzweig M.C. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature 2019 570 7762 468 473 10.1038/s41586‑019‑1250‑z 31142836
    [Google Scholar]
  125. Saunders K.O. Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques. bioRxiv 2023 2023.03
    [Google Scholar]
  126. Musharrafieh R. Germline-targeting chimpanzee SIV Envelopes induce V2-apex broadly neutralizing-like B cell precursors in a rhesus macaque infection model. bioRxiv 2023 2023.09
    [Google Scholar]
  127. Cancro M.P. Tomayko M.M. Memory B cells and plasma cells: The differentiative continuum of humoral immunity. Immunol. Rev. 2021 303 1 72 82 10.1111/imr.13016 34396546
    [Google Scholar]
  128. Akkaya M. Kwak K. Pierce S.K. B cell memory: Building two walls of protection against pathogens. Nat. Rev. Immunol. 2020 20 4 229 238 10.1038/s41577‑019‑0244‑2 31836872
    [Google Scholar]
  129. Victora G.D. Nussenzweig M.C. Germinal centers. Annu. Rev. Immunol. 2012 30 1 429 457 10.1146/annurev‑immunol‑020711‑075032 22224772
    [Google Scholar]
  130. Mesin L. Ersching J. Victora G.D. Germinal center B cell dynamics. Immunity 2016 45 3 471 482 10.1016/j.immuni.2016.09.001 27653600
    [Google Scholar]
  131. Young C. Brink R. The unique biology of germinal center B cells. Immunity 2021 54 8 1652 1664 10.1016/j.immuni.2021.07.015 34380063
    [Google Scholar]
  132. Havenar-Daughton C. Sarkar A. Kulp D.W. Toy L. Hu X. Deresa I. Kalyuzhniy O. Kaushik K. Upadhyay A.A. Menis S. Landais E. Cao L. Diedrich J.K. Kumar S. Schiffner T. Reiss S.M. Seumois G. Yates J.R. Paulson J.C. Bosinger S.E. Wilson I.A. Schief W.R. Crotty S. The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Sci. Transl. Med. 2018 10 448 eaat0381 10.1126/scitranslmed.aat0381 29973404
    [Google Scholar]
  133. Steichen J.M. Kulp D.W. Tokatlian T. Escolano A. Dosenovic P. Stanfield R.L. McCoy L.E. Ozorowski G. Hu X. Kalyuzhniy O. Briney B. Schiffner T. Garces F. Freund N.T. Gitlin A.D. Menis S. Georgeson E. Kubitz M. Adachi Y. Jones M. Mutafyan A.A. Yun D.S. Mayer C.T. Ward A.B. Burton D.R. Wilson I.A. Irvine D.J. Nussenzweig M.C. Schief W.R. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 2016 45 3 483 496 10.1016/j.immuni.2016.08.016 27617678
    [Google Scholar]
  134. LaBranche C.C. Henderson R. Hsu A. Behrens S. Chen X. Zhou T. Wiehe K. Saunders K.O. Alam S.M. Bonsignori M. Borgnia M.J. Sattentau Q.J. Eaton A. Greene K. Gao H. Liao H.X. Williams W.B. Peacock J. Tang H. Perez L.G. Edwards R.J. Kepler T.B. Korber B.T. Kwong P.D. Mascola J.R. Acharya P. Haynes B.F. Montefiori D.C. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathog. 2019 15 9 e1008026 10.1371/journal.ppat.1008026 31527908
    [Google Scholar]
  135. Bonsignori M. Liao H.X. Gao F. Williams W.B. Alam S.M. Montefiori D.C. Haynes B.F. Antibody‐virus co‐evolution in HIV infection: Paths for HIV vaccine development. Immunol. Rev. 2017 275 1 145 160 10.1111/imr.12509 28133802
    [Google Scholar]
  136. Malherbe D.C. Doria-Rose N.A. Misher L. Beckett T. Puryear W.B. Schuman J.T. Kraft Z. O’Malley J. Mori M. Srivastava I. Barnett S. Stamatatos L. Haigwood N.L. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 2011 85 11 5262 5274 10.1128/JVI.02419‑10 21430056
    [Google Scholar]
  137. Saunders K.O. Wiehe K. Tian M. Acharya P. Bradley T. Alam S.M. Go E.P. Scearce R. Sutherland L. Henderson R. Hsu A.L. Borgnia M.J. Chen H. Lu X. Wu N.R. Watts B. Jiang C. Easterhoff D. Cheng H.L. McGovern K. Waddicor P. Chapdelaine-Williams A. Eaton A. Zhang J. Rountree W. Verkoczy L. Tomai M. Lewis M.G. Desaire H.R. Edwards R.J. Cain D.W. Bonsignori M. Montefiori D. Alt F.W. Haynes B.F. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science 2019 366 6470 eaay7199 10.1126/science.aay7199 31806786
    [Google Scholar]
  138. Bonsignori M. Scott E. Wiehe K. Easterhoff D. Alam S.M. Hwang K.K. Cooper M. Xia S.M. Zhang R. Montefiori D.C. Henderson R. Nie X. Kelsoe G. Moody M.A. Chen X. Joyce M.G. Kwong P.D. Connors M. Mascola J.R. McGuire A.T. Stamatatos L. Medina-Ramírez M. Sanders R.W. Saunders K.O. Kepler T.B. Haynes B.F. Inference of the HIV-1 VRC01 antibody lineage unmutated common ancestor reveals alternative pathways to overcome a key glycan barrier. Immunity 2018 49 6 1162 1174.e8 10.1016/j.immuni.2018.10.015 30552024
    [Google Scholar]
  139. Landais E. Murrell B. Briney B. Murrell S. Rantalainen K. Berndsen Z.T. Ramos A. Wickramasinghe L. Smith M.L. Eren K. de Val N. Wu M. Cappelletti A. Umotoy J. Lie Y. Wrin T. Algate P. Chan-Hui P.Y. Karita E. Ward A.B. Wilson I.A. Burton D.R. Smith D. Pond S.L.K. Poignard P. IAVI Protocol C Investigators IAVI African HIV Research Network HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 apex broadly neutralizing antibody lineage. Immunity 2017 47 5 990 1003.e9 10.1016/j.immuni.2017.11.002 29166592
    [Google Scholar]
  140. Willis J.R. Berndsen Z.T. Ma K.M. Steichen J.M. Schiffner T. Landais E. Liguori A. Kalyuzhniy O. Allen J.D. Baboo S. Omorodion O. Diedrich J.K. Hu X. Georgeson E. Phelps N. Eskandarzadeh S. Groschel B. Kubitz M. Adachi Y. Mullin T.M. Alavi N.B. Falcone S. Himansu S. Carfi A. Wilson I.A. Yates J.R. III Paulson J.C. Crispin M. Ward A.B. Schief W.R. Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity 2022 55 11 2149 2167.e9 10.1016/j.immuni.2022.09.001 36179689
    [Google Scholar]
  141. Liu M. Yang G. Wiehe K. Nicely N.I. Vandergrift N.A. Rountree W. Bonsignori M. Alam S.M. Gao J. Haynes B.F. Kelsoe G. Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 2015 89 1 784 798 10.1128/JVI.02378‑14 25355869
    [Google Scholar]
  142. Williams W.B. Zhang J. Jiang C. Nicely N.I. Fera D. Luo K. Moody M.A. Liao H.X. Alam S.M. Kepler T.B. Ramesh A. Wiehe K. Holland J.A. Bradley T. Vandergrift N. Saunders K.O. Parks R. Foulger A. Xia S.M. Bonsignori M. Montefiori D.C. Louder M. Eaton A. Santra S. Scearce R. Sutherland L. Newman A. Bouton-Verville H. Bowman C. Bomze H. Gao F. Marshall D.J. Whitesides J.F. Nie X. Kelsoe G. Reed S.G. Fox C.B. Clary K. Koutsoukos M. Franco D. Mascola J.R. Harrison S.C. Haynes B.F. Verkoczy L. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nat. Commun. 2017 8 1 1732 10.1038/s41467‑017‑01336‑3 29170366
    [Google Scholar]
  143. Tian M. McGovern K. Cheng H.L. Waddicor P. Rieble L. Dao M. Chen Y. Kimble M.T. Cantor E. Manfredonia N. Judson R. Chapdelaine-Williams A. Cain D.W. Haynes B.F. Alt F.W. Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. Proc. Natl. Acad. Sci. USA 2020 117 14 7929 7940 10.1073/pnas.1921996117 32209668
    [Google Scholar]
  144. Schiffner T. Vaccination induces broadly neutralizing antibody precursors to HIV gp41. Nat. Immunol. 2024 1 10
    [Google Scholar]
  145. Habib R. Deep mining of the human antibody repertoire identifies frequent and immunogenetically diverse CDRH3 topologies targetable by vaccination. bioRxiv 2024 2024.10
    [Google Scholar]
  146. Jumper J. Evans R. Pritzel A. Green T. Figurnov M. Ronneberger O. Tunyasuvunakool K. Bates R. Žídek A. Potapenko A. Bridgland A. Meyer C. Kohl S.A.A. Ballard A.J. Cowie A. Romera-Paredes B. Nikolov S. Jain R. Adler J. Back T. Petersen S. Reiman D. Clancy E. Zielinski M. Steinegger M. Pacholska M. Berghammer T. Bodenstein S. Silver D. Vinyals O. Senior A.W. Kavukcuoglu K. Kohli P. Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature 2021 596 7873 583 589 10.1038/s41586‑021‑03819‑2 34265844
    [Google Scholar]
  147. Olsen T.H. Boyles F. Deane C.M. Observed antibody space: A diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 2022 31 1 141 146 10.1002/pro.4205 34655133
    [Google Scholar]
  148. Wang J. Lin F. Wan Z. Sun X. Lu Y. Huang J. Wang F. Zeng Y. Chen Y.H. Shi Y. Zheng W. Li Z. Xiong C. Liu W. Profiling the origin, dynamics, and function of traction force in B cell activation. Sci. Signal. 2018 11 542 eaai9192 10.1126/scisignal.aai9192 30087179
    [Google Scholar]
  149. Ortiz Y. Anasti K. Kane A.P. Cronin K. Alam S.M. Reth M. The CH1 domain influences the expression and antigen sensing of the HIV-specific CH31 IgM-BCR and IgG-BCR. Proc. Natl. Acad. Sci. USA 2024 121 31 e2404728121 10.1073/pnas.2404728121 39042672
    [Google Scholar]
  150. Wan Z. Chen X. Chen H. Ji Q. Chen Y. Wang J. Cao Y. Wang F. Lou J. Tang Z. Liu W. The activation of IgM- or isotype-switched IgG- and IgE-BCR exhibits distinct mechanical force sensitivity and threshold. eLife 2015 4 e06925 10.7554/eLife.06925 26258882
    [Google Scholar]
  151. Degn S.E. Tolar P. Towards a unifying model for B-cell receptor triggering. Nat. Rev. Immunol. 2024 ••• 1 15 39256626
    [Google Scholar]
  152. Brooks J.F. Riggs J. Mueller J.L. Mathenge R. Wholey W.Y. Meyer A.R. Yoda S.T. Vykunta V.S. Nielsen H.V. Cheng W. Zikherman J. Molecular basis for potent B cell responses to antigen displayed on particles of viral size. Nat. Immunol. 2023 24 10 1762 1777 10.1038/s41590‑023‑01597‑9 37653247
    [Google Scholar]
  153. Hossain M.A. Anasti K. Watts B. Cronin K. Derking R. Groschel B. Kane A.P. Edwards R.J. Easterhoff D. Zhang J. Rountree W. Ortiz Y. Saunders K. Schief W.R. Sanders R.W. Verkoczy L. Reth M. Alam S.M. B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. Cell Rep. 2022 39 13 111021 10.1016/j.celrep.2022.111021 35767950
    [Google Scholar]
  154. Escolano A. Steichen J.M. Dosenovic P. Kulp D.W. Golijanin J. Sok D. Freund N.T. Gitlin A.D. Oliveira T. Araki T. Lowe S. Chen S.T. Heinemann J. Yao K.H. Georgeson E. Saye-Francisco K.L. Gazumyan A. Adachi Y. Kubitz M. Burton D.R. Schief W.R. Nussenzweig M.C. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 2016 166 6 1445 1458.e12 10.1016/j.cell.2016.07.030 27610569
    [Google Scholar]
  155. Wiehe K. Saunders K.O. Stalls V. Cain D.W. Venkatayogi S. Martin Beem J.S. Berry M. Evangelous T. Henderson R. Hora B. Xia S.M. Jiang C. Newman A. Bowman C. Lu X. Bryan M.E. Bal J. Sanzone A. Chen H. Eaton A. Tomai M.A. Fox C.B. Tam Y.K. Barbosa C. Bonsignori M. Muramatsu H. Alam S.M. Montefiori D.C. Williams W.B. Pardi N. Tian M. Weissman D. Alt F.W. Acharya P. Haynes B.F. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction. Cell Host Microbe 2024 32 5 693 709.e7 10.1016/j.chom.2024.04.006 38670093
    [Google Scholar]
  156. Zhang R. Verkoczy L. Wiehe K. Munir Alam S. Nicely N.I. Santra S. Bradley T. Pemble C.W. IV Zhang J. Gao F. Montefiori D.C. Bouton-Verville H. Kelsoe G. Larimore K. Greenberg P.D. Parks R. Foulger A. Peel J.N. Luo K. Lu X. Trama A.M. Vandergrift N. Tomaras G.D. Kepler T.B. Moody M.A. Liao H.X. Haynes B.F. Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages. Sci. Transl. Med. 2016 8 336 336ra62 10.1126/scitranslmed.aaf0618 27122615
    [Google Scholar]
  157. Luo S. Jing C. Ye A.Y. Kratochvil S. Cottrell C.A. Koo J.H. Chapdelaine Williams A. Francisco L.V. Batra H. Lamperti E. Kalyuzhniy O. Zhang Y. Barbieri A. Manis J.P. Haynes B.F. Schief W.R. Batista F.D. Tian M. Alt F.W. Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors. Proc. Natl. Acad. Sci. USA 2023 120 1 e2217883120 10.1073/pnas.2217883120 36574685
    [Google Scholar]
  158. Tas J.M.J. Koo J.H. Lin Y.C. Xie Z. Steichen J.M. Jackson A.M. Hauser B.M. Wang X. Cottrell C.A. Torres J.L. Warner J.E. Kirsch K.H. Weldon S.R. Groschel B. Nogal B. Ozorowski G. Bangaru S. Phelps N. Adachi Y. Eskandarzadeh S. Kubitz M. Burton D.R. Lingwood D. Schmidt A.G. Nair U. Ward A.B. Schief W.R. Batista F.D. Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. Immunity 2022 55 10 1856 1871.e6 10.1016/j.immuni.2022.07.020 35987201
    [Google Scholar]
  159. Wang X. Cottrell C.A. Hu X. Ray R. Bottermann M. Villavicencio P.M. Yan Y. Xie Z. Warner J.E. Ellis-Pugh J.R. Kalyuzhniy O. Liguori A. Willis J.R. Menis S. Rämisch S. Eskandarzadeh S. Kubitz M. Tingle R. Phelps N. Groschel B. Himansu S. Carfi A. Kirsch K.H. Weldon S.R. Nair U. Schief W.R. Batista F.D. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models. Sci. Immunol. 2024 9 95 eadn0622 10.1126/sciimmunol.adn0622 38753808
    [Google Scholar]
  160. Dosenovic P. Kara E.E. Pettersson A.K. McGuire A.T. Gray M. Hartweger H. Thientosapol E.S. Stamatatos L. Nussenzweig M.C. Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proc. Natl. Acad. Sci. USA 2018 115 18 4743 4748 10.1073/pnas.1803457115 29666227
    [Google Scholar]
  161. Xie Z. Lin Y.C. Steichen J.M. Ozorowski G. Kratochvil S. Ray R. Torres J.L. Liguori A. Kalyuzhniy O. Wang X. Warner J.E. Weldon S.R. Dale G.A. Kirsch K.H. Nair U. Baboo S. Georgeson E. Adachi Y. Kubitz M. Jackson A.M. Richey S.T. Volk R.M. Lee J.H. Diedrich J.K. Prum T. Falcone S. Himansu S. Carfi A. Yates J.R. III Paulson J.C. Sok D. Ward A.B. Schief W.R. Batista F.D. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 2024 384 6697 eadk0582 10.1126/science.adk0582 38753770
    [Google Scholar]
  162. Caniels T.G. Medina-Ramìrez M. Zhang S. Kratochvil S. Xian Y. Koo J.H. Derking R. Samsel J. van Schooten J. Pecetta S. Lamperti E. Yuan M. Carrasco M.R. del Moral Sánchez I. Allen J.D. Bouhuijs J.H. Yasmeen A. Ketas T.J. Snitselaar J.L. Bijl T.P.L. Martin I.C. Torres J.L. Cupo A. Shirreff L. Rogers K. Mason R.D. Roederer M. Greene K.M. Gao H. Silva C.M. Baken I.J.L. Tian M. Alt F.W. Pulendran B. Seaman M.S. Crispin M. van Gils M.J. Montefiori D.C. McDermott A.B. Villinger F.J. Koup R.A. Moore J.P. Klasse P.J. Ozorowski G. Batista F.D. Wilson I.A. Ward A.B. Sanders R.W. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Sci. Immunol. 2024 9 98 eadk9550 10.1126/sciimmunol.adk9550 39213338
    [Google Scholar]
  163. Saunders K.O. Edwards R.J. Tilahun K. Manne K. Lu X. Cain D.W. Wiehe K. Williams W.B. Mansouri K. Hernandez G.E. Sutherland L. Scearce R. Parks R. Barr M. DeMarco T. Eater C.M. Eaton A. Morton G. Mildenberg B. Wang Y. Rountree R.W. Tomai M.A. Fox C.B. Moody M.A. Alam S.M. Santra S. Lewis M.G. Denny T.N. Shaw G.M. Montefiori D.C. Acharya P. Haynes B.F. Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. Sci. Transl. Med. 2022 14 661 eabo5598 10.1126/scitranslmed.abo5598 36070369
    [Google Scholar]
  164. Steichen J.M. Phung I. Salcedo E. Ozorowski G. Willis J.R. Baboo S. Liguori A. Cottrell C.A. Torres J.L. Madden P.J. Ma K.M. Sutton H.J. Lee J.H. Kalyuzhniy O. Allen J.D. Rodriguez O.L. Adachi Y. Mullen T.M. Georgeson E. Kubitz M. Burns A. Barman S. Mopuri R. Metz A. Altheide T.K. Diedrich J.K. Saha S. Shields K. Schultze S.E. Smith M.L. Schiffner T. Burton D.R. Watson C.T. Bosinger S.E. Crispin M. Yates J.R. III Paulson J.C. Ward A.B. Sok D. Crotty S. Schief W.R. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates. Science 2024 384 6697 eadj8321 10.1126/science.adj8321 38753769
    [Google Scholar]
  165. Roark R.S. Li H. Williams W.B. Chug H. Mason R.D. Gorman J. Wang S. Lee F.H. Rando J. Bonsignori M. Hwang K.K. Saunders K.O. Wiehe K. Moody M.A. Hraber P.T. Wagh K. Giorgi E.E. Russell R.M. Bibollet-Ruche F. Liu W. Connell J. Smith A.G. DeVoto J. Murphy A.I. Smith J. Ding W. Zhao C. Chohan N. Okumura M. Rosario C. Ding Y. Lindemuth E. Bauer A.M. Bar K.J. Ambrozak D. Chao C.W. Chuang G.Y. Geng H. Lin B.C. Louder M.K. Nguyen R. Zhang B. Lewis M.G. Raymond D.D. Doria-Rose N.A. Schramm C.A. Douek D.C. Roederer M. Kepler T.B. Kelsoe G. Mascola J.R. Kwong P.D. Korber B.T. Harrison S.C. Haynes B.F. Hahn B.H. Shaw G.M. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science 2021 371 6525 eabd2638 10.1126/science.abd2638 33214287
    [Google Scholar]
  166. Roark R.S. HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D gene. bioRxiv 2024 2024.06
    [Google Scholar]
  167. Hora B. Li H. Shen X. Martin M. Chen Y. Berry M. Evangelous T. Macintyre A.N. Arus-Altuz A. Wang S. Singh A. Zhao C. De Naeyer N. DeMarco T. Kuykendall C. Gurley T. Saunders K.O. Denny T. Moody M.A. Misamore J. Lewis M.G. Wiehe K. Cain D.W. Montefiori D.C. Shaw G.M. Williams W.B. Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies. Cell Rep. 2023 42 3 112255 10.1016/j.celrep.2023.112255 36924501
    [Google Scholar]
  168. Doores K.J. Bonomelli C. Harvey D.J. Vasiljevic S. Dwek R.A. Burton D.R. Crispin M. Scanlan C.N. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA 2010 107 31 13800 13805 10.1073/pnas.1006498107 20643940
    [Google Scholar]
  169. Go E.P. Liao H.X. Alam S.M. Hua D. Haynes B.F. Desaire H. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 2013 12 3 1223 1234 10.1021/pr300870t 23339644
    [Google Scholar]
  170. Pritchard L.K. Spencer D.I.R. Royle L. Bonomelli C. Seabright G.E. Behrens A.J. Kulp D.W. Menis S. Krumm S.A. Dunlop D.C. Crispin D.J. Bowden T.A. Scanlan C.N. Ward A.B. Schief W.R. Doores K.J. Crispin M. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat. Commun. 2015 6 1 7479 10.1038/ncomms8479 26105115
    [Google Scholar]
  171. McGuire A.T. Gray M.D. Dosenovic P. Gitlin A.D. Freund N.T. Petersen J. Correnti C. Johnsen W. Kegel R. Stuart A.B. Glenn J. Seaman M.S. Schief W.R. Strong R.K. Nussenzweig M.C. Stamatatos L. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun. 2016 7 1 10618 10.1038/ncomms10618 26907590
    [Google Scholar]
  172. Ahmed F.K. Clark B.E. Burton D.R. Pantophlet R. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine 2012 30 5 922 930 10.1016/j.vaccine.2011.11.089 22142583
    [Google Scholar]
  173. Forsell M.N.E. Soldemo M. Dosenovic P. Wyatt R.T. Karlsson M.C.I. Karlsson Hedestam G.B. Independent expansion of epitope-specific plasma cell responses upon HIV-1 envelope glycoprotein immunization. J. Immunol. 2013 191 1 44 51 10.4049/jimmunol.1203087 23740950
    [Google Scholar]
  174. Lin S.C. Liu W.C. Jan J.T. Wu S.C. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One 2014 9 3 e92822 10.1371/journal.pone.0092822 24671139
    [Google Scholar]
  175. Duan H. Chen X. Boyington J.C. Cheng C. Zhang Y. Jafari A.J. Stephens T. Tsybovsky Y. Kalyuzhniy O. Zhao P. Menis S. Nason M.C. Normandin E. Mukhamedova M. DeKosky B.J. Wells L. Schief W.R. Tian M. Alt F.W. Kwong P.D. Mascola J.R. Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-class precursor antibodies. Immunity 2018 49 2 301 311.e5 10.1016/j.immuni.2018.07.005 30076101
    [Google Scholar]
  176. Reeves P.J. Callewaert N. Contreras R. Khorana H.G. Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N -acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. USA 2002 99 21 13419 13424 10.1073/pnas.212519299 12370423
    [Google Scholar]
  177. Crooks E.T. Grimley S.L. Cully M. Osawa K. Dekkers G. Saunders K. Rämisch S. Menis S. Schief W.R. Doria-Rose N. Haynes B. Murrell B. Cale E.M. Pegu A. Mascola J.R. Vidarsson G. Binley J.M. Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation. PLoS Pathog. 2018 14 5 e1007024 10.1371/journal.ppat.1007024 29718999
    [Google Scholar]
  178. LaBranche C.C. McGuire A.T. Gray M.D. Behrens S. Zhou T. Sattentau Q.J. Peacock J. Eaton A. Greene K. Gao H. Tang H. Perez L.G. Saunders K.O. Mascola J.R. Haynes B.F. Stamatatos L. Montefiori D.C. Mascola J.R. Haynes B.F. Stamatatos L. Montefiori D.C. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathog. 2018 14 11 e1007431 10.1371/journal.ppat.1007431 30395637
    [Google Scholar]
  179. Julien J.P. Cupo A. Sok D. Stanfield R.L. Lyumkis D. Deller M.C. Klasse P.J. Burton D.R. Sanders R.W. Moore J.P. Ward A.B. Wilson I.A. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013 342 6165 1477 1483 10.1126/science.1245625 24179159
    [Google Scholar]
  180. Pancera M. Zhou T. Druz A. Georgiev I.S. Soto C. Gorman J. Huang J. Acharya P. Chuang G.Y. Ofek G. Stewart-Jones G.B.E. Stuckey J. Bailer R.T. Joyce M.G. Louder M.K. Tumba N. Yang Y. Zhang B. Cohen M.S. Haynes B.F. Mascola J.R. Morris L. Munro J.B. Blanchard S.C. Mothes W. Connors M. Kwong P.D. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014 514 7523 455 461 10.1038/nature13808 25296255
    [Google Scholar]
  181. Aussedat B. Vohra Y. Park P.K. Fernández-Tejada A. Alam S.M. Dennison S.M. Jaeger F.H. Anasti K. Stewart S. Blinn J.H. Liao H.X. Sodroski J.G. Haynes B.F. Danishefsky S.J. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J. Am. Chem. Soc. 2013 135 35 13113 13120 10.1021/ja405990z 23915436
    [Google Scholar]
  182. Alam S.M. Dennison S.M. Aussedat B. Vohra Y. Park P.K. Fernández-Tejada A. Stewart S. Jaeger F.H. Anasti K. Blinn J.H. Kepler T.B. Bonsignori M. Liao H.X. Sodroski J.G. Danishefsky S.J. Haynes B.F. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc. Natl. Acad. Sci. USA 2013 110 45 18214 18219 10.1073/pnas.1317855110 24145434
    [Google Scholar]
  183. Cottrell C.A. Hu X. Lee J.H. Skog P. Luo S. Flynn C.T. McKenney K.R. Hurtado J. Kalyuzhniy O. Liguori A. Willis J.R. Landais E. Raemisch S. Chen X. Baboo S. Himansu S. Diedrich J.K. Duan H. Cheng C. Schiffner T. Bader D.L.V. Kulp D.W. Tingle R. Georgeson E. Eskandarzadeh S. Alavi N. Lu D. Sincomb T. Kubitz M. Mullen T.M. Yates J.R. III Paulson J.C. Mascola J.R. Alt F.W. Briney B. Sok D. Schief W.R. Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. Sci. Transl. Med. 2024 16 748 eadn0223 10.1126/scitranslmed.adn0223 38753806
    [Google Scholar]
  184. Travieso T. Li J. Mahesh S. Mello J.D.F.R.E. Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines 2022 7 1 75 10.1038/s41541‑022‑00503‑y 35787629
    [Google Scholar]
  185. Caniels T.G. Medina-Ramírez M. Zhang J. Sarkar A. Kumar S. LaBranche A. Derking R. Allen J.D. Snitselaar J.L. Capella-Pujol J. Sánchez I.M. Yasmeen A. Diaz M. Aldon Y. Bijl T.P.L. Venkatayogi S. Martin Beem J.S. Newman A. Jiang C. Lee W.H. Pater M. Burger J.A. van Breemen M.J. de Taeye S.W. Rantalainen K. LaBranche C. Saunders K.O. Montefiori D. Ozorowski G. Ward A.B. Crispin M. Moore J.P. Klasse P.J. Haynes B.F. Wilson I.A. Wiehe K. Verkoczy L. Sanders R.W. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell Rep. Med. 2023 4 4 101003 10.1016/j.xcrm.2023.101003 37044090
    [Google Scholar]
  186. Polack F.P. Thomas S.J. Kitchin N. Absalon J. Gurtman A. Lockhart S. Perez J.L. Pérez Marc G. Moreira E.D. Zerbini C. Bailey R. Swanson K.A. Roychoudhury S. Koury K. Li P. Kalina W.V. Cooper D. Frenck R.W. Jr Hammitt L.L. Türeci Ö. Nell H. Schaefer A. Ünal S. Tresnan D.B. Mather S. Dormitzer P.R. Şahin U. Jansen K.U. Gruber W.C. C4591001 Clinical Trial Group Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020 383 27 2603 2615 10.1056/NEJMoa2034577 33301246
    [Google Scholar]
  187. Wang F. Kream R.M. Stefano G.B. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med. Sci. Monit. 2020 26 e924700 e924701 10.12659/MSM.924700 32366816
    [Google Scholar]
  188. Iavarone C. O’hagan D.T. Yu D. Delahaye N.F. Ulmer J.B. Mechanism of action of mRNA-based vaccines. Expert Rev. Vaccines 2017 16 9 871 881 10.1080/14760584.2017.1355245 28701102
    [Google Scholar]
  189. Ahmed S. Herschhorn A. mRNA-based HIV-1 vaccines. Clin. Microbiol. Rev. 2024 37 3 e00041-24 10.1128/cmr.00041‑24 39016564
    [Google Scholar]
  190. Yang Shih T-A. Meffre E. Roederer M. Nussenzweig M.C. Role of BCR affinity in T cell–dependent antibody responses in vivo. Nat. Immunol. 2002 3 6 570 575 10.1038/ni803 12021782
    [Google Scholar]
  191. Dal Porto J.M. Haberman A.M. Kelsoe G. Shlomchik M.J. Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J. Exp. Med. 2002 195 9 1215 1221 10.1084/jem.20011550 11994427
    [Google Scholar]
  192. Kiaie S.H. Majidi Zolbanin N. Ahmadi A. Bagherifar R. Valizadeh H. Kashanchi F. Jafari R. Recent advances in mRNA-LNP therapeutics: Immunological and pharmacological aspects. J. Nanobiotechnology 2022 20 1 276 10.1186/s12951‑022‑01478‑7 35701851
    [Google Scholar]
  193. Mietzner R. Barbey C. Lehr H. Ziegler C.E. Peterhoff D. Wagner R. Goepferich A. Breunig M. Prolonged delivery of HIV-1 vaccine nanoparticles from hydrogels. Int. J. Pharm. 2024 657 124131 10.1016/j.ijpharm.2024.124131 38643811
    [Google Scholar]
  194. Roth G.A. Gale E.C. Alcántara-Hernández M. Luo W. Axpe E. Verma R. Yin Q. Yu A.C. Lopez Hernandez H. Maikawa C.L. Smith A.A.A. Davis M.M. Pulendran B. Idoyaga J. Appel E.A. Injectable hydrogels for sustained codelivery of subunit vaccines enhance humoral immunity. ACS Cent. Sci. 2020 6 10 1800 1812 10.1021/acscentsci.0c00732 33145416
    [Google Scholar]
  195. Tam H.H. Melo M.B. Kang M. Pelet J.M. Ruda V.M. Foley M.H. Hu J.K. Kumari S. Crampton J. Baldeon A.D. Sanders R.W. Moore J.P. Crotty S. Langer R. Anderson D.G. Chakraborty A.K. Irvine D.J. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl. Acad. Sci. USA 2016 113 43 E6639 E6648 10.1073/pnas.1606050113 27702895
    [Google Scholar]
  196. Madden P.J. Diverse priming outcomes under conditions of very rare precursor B cells. bioRxiv 2024 2024.11
    [Google Scholar]
  197. Reed S.G. Orr M.T. Fox C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013 19 12 1597 1608 10.1038/nm.3409 24309663
    [Google Scholar]
  198. Kasturi S.P. Rasheed M.A.U. Havenar-Daughton C. Pham M. Legere T. Sher Z.J. Kovalenkov Y. Gumber S. Huang J.Y. Gottardo R. Fulp W. Sato A. Sawant S. Stanfield-Oakley S. Yates N. LaBranche C. Alam S.M. Tomaras G. Ferrari G. Montefiori D. Wrammert J. Villinger F. Tomai M. Vasilakos J. Fox C.B. Reed S.G. Haynes B.F. Crotty S. Ahmed R. Pulendran B. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. 2020 5 48 eabb1025 10.1126/sciimmunol.abb1025 32561559
    [Google Scholar]
  199. Hahn W.O. HIV BG505 SOSIP. 664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies. medRxiv 2024 2024.05 10.1101/2024.05.08.24306957
    [Google Scholar]
  200. Silva M. Kato Y. Melo M.B. Phung I. Freeman B.L. Li Z. Roh K. Van Wijnbergen J.W. Watkins H. Enemuo C.A. Hartwell B.L. Chang J.Y.H. Xiao S. Rodrigues K.A. Cirelli K.M. Li N. Haupt S. Aung A. Cossette B. Abraham W. Kataria S. Bastidas R. Bhiman J. Linde C. Bloom N.I. Groschel B. Georgeson E. Phelps N. Thomas A. Bals J. Carnathan D.G. Lingwood D. Burton D.R. Alter G. Padera T.P. Belcher A.M. Schief W.R. Silvestri G. Ruprecht R.M. Crotty S. Irvine D.J. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Sci. Immunol. 2021 6 66 eabf1152 10.1126/sciimmunol.abf1152 34860581
    [Google Scholar]
  201. Lee J.H. Sutton H.J. Cottrell C.A. Phung I. Ozorowski G. Sewall L.M. Nedellec R. Nakao C. Silva M. Richey S.T. Torres J.L. Lee W.H. Georgeson E. Kubitz M. Hodges S. Mullen T.M. Adachi Y. Cirelli K.M. Kaur A. Allers C. Fahlberg M. Grasperge B.F. Dufour J.P. Schiro F. Aye P.P. Kalyuzhniy O. Liguori A. Carnathan D.G. Silvestri G. Shen X. Montefiori D.C. Veazey R.S. Ward A.B. Hangartner L. Burton D.R. Irvine D.J. Schief W.R. Crotty S. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 2022 609 7929 998 1004 10.1038/s41586‑022‑05216‑9 36131022
    [Google Scholar]
  202. Phung I. Rodrigues K.A. Marina-Zárate E. Maiorino L. Pahar B. Lee W.H. Melo M. Kaur A. Allers C. Fahlberg M. Grasperge B.F. Dufour J.P. Schiro F. Aye P.P. Lopez P.G. Torres J.L. Ozorowski G. Eskandarzadeh S. Kubitz M. Georgeson E. Groschel B. Nedellec R. Bick M. Kaczmarek Michaels K. Gao H. Shen X. Carnathan D.G. Silvestri G. Montefiori D.C. Ward A.B. Hangartner L. Veazey R.S. Burton D.R. Schief W.R. Irvine D.J. Crotty S. A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates. Nat. Commun. 2023 14 1 7107 10.1038/s41467‑023‑42923‑x 37925510
    [Google Scholar]
  203. Huang J. Kang B.H. Ishida E. Zhou T. Griesman T. Sheng Z. Wu F. Doria-Rose N.A. Zhang B. McKee K. O’Dell S. Chuang G.Y. Druz A. Georgiev I.S. Schramm C.A. Zheng A. Joyce M.G. Asokan M. Ransier A. Darko S. Migueles S.A. Bailer R.T. Louder M.K. Alam S.M. Parks R. Kelsoe G. Von Holle T. Haynes B.F. Douek D.C. Hirsch V. Seaman M.S. Shapiro L. Mascola J.R. Kwong P.D. Connors M. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 2016 45 5 1108 1121 10.1016/j.immuni.2016.10.027 27851912
    [Google Scholar]
  204. Liao H.X. Lynch R. Zhou T. Gao F. Alam S.M. Boyd S.D. Fire A.Z. Roskin K.M. Schramm C.A. Zhang Z. Zhu J. Shapiro L. Becker J. Benjamin B. Blakesley R. Bouffard G. Brooks S. Coleman H. Dekhtyar M. Gregory M. Guan X. Gupta J. Han J. Hargrove A. Ho S. Johnson T. Legaspi R. Lovett S. Maduro Q. Masiello C. Maskeri B. McDowell J. Montemayor C. Mullikin J. Park M. Riebow N. Schandler K. Schmidt B. Sison C. Stantripop M. Thomas J. Thomas P. Vemulapalli M. Young A. Mullikin J.C. Gnanakaran S. Hraber P. Wiehe K. Kelsoe G. Yang G. Xia S-M. Montefiori D.C. Parks R. Lloyd K.E. Scearce R.M. Soderberg K.A. Cohen M. Kamanga G. Louder M.K. Tran L.M. Chen Y. Cai F. Chen S. Moquin S. Du X. Joyce M.G. Srivatsan S. Zhang B. Zheng A. Shaw G.M. Hahn B.H. Kepler T.B. Korber B.T.M. Kwong P.D. Mascola J.R. Haynes B.F. NISC Comparative Sequencing Program Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013 496 7446 469 476 10.1038/nature12053 23552890
    [Google Scholar]
  205. Scheid J.F. Mouquet H. Ueberheide B. Diskin R. Klein F. Oliveira T.Y.K. Pietzsch J. Fenyo D. Abadir A. Velinzon K. Hurley A. Myung S. Boulad F. Poignard P. Burton D.R. Pereyra F. Ho D.D. Walker B.D. Seaman M.S. Bjorkman P.J. Chait B.T. Nussenzweig M.C. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011 333 6049 1633 1637 10.1126/science.1207227 21764753
    [Google Scholar]
  206. Wu X. Zhang Z. Schramm C.A. Joyce M.G. Do Kwon Y. Zhou T. Sheng Z. Zhang B. O’Dell S. McKee K. Georgiev I.S. Chuang G.Y. Longo N.S. Lynch R.M. Saunders K.O. Soto C. Srivatsan S. Yang Y. Bailer R.T. Louder M.K. Mullikin J.C. Connors M. Kwong P.D. Mascola J.R. Shapiro L. Benjamin B. Blakesley R. Bouffard G. Brooks S. Coleman H. Dekhtyar M. Gregory M. Guan X. Gupta J. Han J. Hargrove A. Ho S. Legaspi R. Maduro Q. Masiello C. Maskeri B. McDowell J. Montemayor C. Park M. Riebow N. Schandler K. Schmidt B. Sison C. Stantripop M. Thomas J. Thomas P. Vemulapalli M. Young A. NISC Comparative Sequencing Program Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 2015 161 3 470 485 10.1016/j.cell.2015.03.004 25865483
    [Google Scholar]
  207. Zhou T. Lynch R.M. Chen L. Acharya P. Wu X. Doria-Rose N.A. Joyce M.G. Lingwood D. Soto C. Bailer R.T. Ernandes M.J. Kong R. Longo N.S. Louder M.K. McKee K. O’Dell S. Schmidt S.D. Tran L. Yang Z. Druz A. Luongo T.S. Moquin S. Srivatsan S. Yang Y. Zhang B. Zheng A. Pancera M. Kirys T. Georgiev I.S. Gindin T. Peng H.P. Yang A.S. Mullikin J.C. Gray M.D. Stamatatos L. Burton D.R. Koff W.C. Cohen M.S. Haynes B.F. Casazza J.P. Connors M. Corti D. Lanzavecchia A. Sattentau Q.J. Weiss R.A. West A.P. Jr Bjorkman P.J. Scheid J.F. Nussenzweig M.C. Shapiro L. Mascola J.R. Kwong P.D. NISC Comparative Sequencing Program Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 2015 161 6 1280 1292 10.1016/j.cell.2015.05.007 26004070
    [Google Scholar]
  208. van Schooten J. Farokhi E. Schorcht A. van den Kerkhof T.L.G.M. Gao H. van der Woude P. Burger J.A. Meesters T.G.R. Bijl T. Ghalaiyini R. Turner H.L. Dorning J. van Schaik B.D.C. van Kampen A.H.C. Labranche C.C. Stanfield R.L. Sok D. Montefiori D.C. Burton D.R. Seaman M.S. Ozorowski G. Wilson I.A. Sanders R.W. Ward A.B. van Gils M.J. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. Nat. Commun. 2022 13 1 4515 10.1038/s41467‑022‑32208‑0 35922441
    [Google Scholar]
  209. Dreja H. Pade C. Chen L. McKnight Á. CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. J. Gen. Virol. 2015 96 7 1899 1905 10.1099/vir.0.000120 25762593
    [Google Scholar]
  210. Wagh K. Bhattacharya T. Williamson C. Robles A. Bayne M. Garrity J. Rist M. Rademeyer C. Yoon H. Lapedes A. Gao H. Greene K. Louder M.K. Kong R. Karim S.A. Burton D.R. Barouch D.H. Nussenzweig M.C. Mascola J.R. Morris L. Montefiori D.C. Korber B. Seaman M.S. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 2016 12 3 e1005520 10.1371/journal.ppat.1005520 27028935
    [Google Scholar]
  211. Corey L. Gilbert P.B. Juraska M. Montefiori D.C. Morris L. Karuna S.T. Edupuganti S. Mgodi N.M. deCamp A.C. Rudnicki E. Huang Y. Gonzales P. Cabello R. Orrell C. Lama J.R. Laher F. Lazarus E.M. Sanchez J. Frank I. Hinojosa J. Sobieszczyk M.E. Marshall K.E. Mukwekwerere P.G. Makhema J. Baden L.R. Mullins J.I. Williamson C. Hural J. McElrath M.J. Bentley C. Takuva S. Gomez Lorenzo M.M. Burns D.N. Espy N. Randhawa A.K. Kochar N. Piwowar-Manning E. Donnell D.J. Sista N. Andrew P. Kublin J.G. Gray G. Ledgerwood J.E. Mascola J.R. Cohen M.S. HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 2021 384 11 1003 1014 10.1056/NEJMoa2031738 33730454
    [Google Scholar]
  212. Magaret C.A. Benkeser D.C. Williamson B.D. Borate B.R. Carpp L.N. Georgiev I.S. Setliff I. Dingens A.S. Simon N. Carone M. Simpkins C. Montefiori D. Alter G. Yu W.H. Juraska M. Edlefsen P.T. Karuna S. Mgodi N.M. Edugupanti S. Gilbert P.B. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLOS Comput. Biol. 2019 15 4 e1006952 10.1371/journal.pcbi.1006952 30933973
    [Google Scholar]
  213. West A.P. Jr Diskin R. Nussenzweig M.C. Bjorkman P.J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 2012 109 30 E2083 E2090 10.1073/pnas.1208984109 22745174
    [Google Scholar]
  214. Schommers P. Gruell H. Abernathy M.E. Tran M.K. Dingens A.S. Gristick H.B. Barnes C.O. Schoofs T. Schlotz M. Vanshylla K. Kreer C. Weiland D. Holtick U. Scheid C. Valter M.M. van Gils M.J. Sanders R.W. Vehreschild J.J. Cornely O.A. Lehmann C. Fätkenheuer G. Seaman M.S. Bloom J.D. Bjorkman P.J. Klein F. Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody. Cell 2020 180 3 471 489.e22 10.1016/j.cell.2020.01.010 32004464
    [Google Scholar]
  215. Matassoli F. Cagigi A. Shen C.H. Henry A.R. Johnston T.S. Schramm C.A. Cottrell C.A. Kalyuzhniy O. Spangler A. Ndung’u T. Dong K. Eller L. Robb M. Eller M. Naluyima P. Kwong P.D. Douek D.C. Schief W.R. Andrews S.F. McDermott A.B. High frequency of HIV precursor-target-specific B cells in sub-Saharan populations. Cell Rep. 2023 42 12 113450 10.1016/j.celrep.2023.113450 38019653
    [Google Scholar]
  216. Lin Y.R. Parks K.R. Weidle C. Naidu A.S. Khechaduri A. Riker A.O. Takushi B. Chun J.H. Borst A.J. Veesler D. Stuart A. Agrawal P. Gray M. Pancera M. Huang P.S. Stamatatos L. HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors. Immunity 2020 53 4 840 851.e6 10.1016/j.immuni.2020.09.007 33053332
    [Google Scholar]
  217. Bonsignori M. Zhou T. Sheng Z. Chen L. Gao F. Joyce M.G. Ozorowski G. Chuang G.Y. Schramm C.A. Wiehe K. Alam S.M. Bradley T. Gladden M.A. Hwang K.K. Iyengar S. Kumar A. Lu X. Luo K. Mangiapani M.C. Parks R.J. Song H. Acharya P. Bailer R.T. Cao A. Druz A. Georgiev I.S. Kwon Y.D. Louder M.K. Zhang B. Zheng A. Hill B.J. Kong R. Soto C. Mullikin J.C. Douek D.C. Montefiori D.C. Moody M.A. Shaw G.M. Hahn B.H. Kelsoe G. Hraber P.T. Korber B.T. Boyd S.D. Fire A.Z. Kepler T.B. Shapiro L. Ward A.B. Mascola J.R. Liao H.X. Kwong P.D. Haynes B.F. NISC Comparative Sequencing Program Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 2016 165 2 449 463 10.1016/j.cell.2016.02.022 26949186
    [Google Scholar]
  218. Gao F. Bonsignori M. Liao H.X. Kumar A. Xia S.M. Lu X. Cai F. Hwang K.K. Song H. Zhou T. Lynch R.M. Alam S.M. Moody M.A. Ferrari G. Berrong M. Kelsoe G. Shaw G.M. Hahn B.H. Montefiori D.C. Kamanga G. Cohen M.S. Hraber P. Kwong P.D. Korber B.T. Mascola J.R. Kepler T.B. Haynes B.F. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 2014 158 3 481 491 10.1016/j.cell.2014.06.022 25065977
    [Google Scholar]
  219. Leggat D.J. Cohen K.W. Willis J.R. Fulp W.J. deCamp A.C. Kalyuzhniy O. Cottrell C.A. Menis S. Finak G. Ballweber-Fleming L. Srikanth A. Plyler J.R. Schiffner T. Liguori A. Rahaman F. Lombardo A. Philiponis V. Whaley R.E. Seese A. Brand J. Ruppel A.M. Hoyland W. Yates N.L. Williams L.D. Greene K. Gao H. Mahoney C.R. Corcoran M.M. Cagigi A. Taylor A. Brown D.M. Ambrozak D.R. Sincomb T. Hu X. Tingle R. Georgeson E. Eskandarzadeh S. Alavi N. Lu D. Mullen T.M. Kubitz M. Groschel B. Maenza J. Kolokythas O. Khati N. Bethony J. Crotty S. Roederer M. Karlsson Hedestam G.B. Tomaras G.D. Montefiori D. Diemert D. Koup R.A. Laufer D.S. McElrath M.J. McDermott A.B. Schief W.R. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 2022 378 6623 eadd6502 10.1126/science.add6502 36454825
    [Google Scholar]
  220. Cohen K.W. De Rosa S.C. Fulp W.J. deCamp A.C. Fiore-Gartland A. Mahoney C.R. Furth S. Donahue J. Whaley R.E. Ballweber-Fleming L. Seese A. Schwedhelm K. Geraghty D. Finak G. Menis S. Leggat D.J. Rahaman F. Lombardo A. Borate B.R. Philiponis V. Maenza J. Diemert D. Kolokythas O. Khati N. Bethony J. Hyrien O. Laufer D.S. Koup R.A. McDermott A.B. Schief W.R. McElrath M.J. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Sci. Transl. Med. 2023 15 697 eadf3309 10.1126/scitranslmed.adf3309 37224227
    [Google Scholar]
  221. Straten K.d. Safety profile and immunogenicity of a phase i clinical trial using germline-targeting trimer GT1.1. Conference on Retroviruses and Opportunistic Infections (CROI) Denver, Colorado 2024.
    [Google Scholar]
  222. Gray M.D. Feng J. Weidle C.E. Cohen K.W. Ballweber-Fleming L. MacCamy A.J. Huynh C.N. Trichka J.J. Montefiori D. Ferrari G. Pancera M. McElrath M.J. Stamatatos L. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. Sci. Adv. 2022 8 18 eabm3948 10.1126/sciadv.abm3948 35507661
    [Google Scholar]
  223. Havenar-Daughton C. Lee J.H. Crotty S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol. Rev. 2017 275 1 49 61 10.1111/imr.12512 28133798
    [Google Scholar]
  224. Escolano A. Gristick H.B. Gautam R. DeLaitsch A.T. Abernathy M.E. Yang Z. Wang H. Hoffmann M.A.G. Nishimura Y. Wang Z. Koranda N. Kakutani L.M. Gao H. Gnanapragasam P.N.P. Raina H. Gazumyan A. Cipolla M. Oliveira T.Y. Ramos V. Irvine D.J. Silva M. West A.P. Jr Keeffe J.R. Barnes C.O. Seaman M.S. Nussenzweig M.C. Martin M.A. Bjorkman P.J. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Sci. Transl. Med. 2021 13 621 eabk1533 10.1126/scitranslmed.abk1533 34818054
    [Google Scholar]
  225. Havenar-Daughton C. Carnathan D.G. Torrents de la Peña A. Pauthner M. Briney B. Reiss S.M. Wood J.S. Kaushik K. van Gils M.J. Rosales S.L. van der Woude P. Locci M. Le K.M. de Taeye S.W. Sok D. Mohammed A.U.R. Huang J. Gumber S. Garcia A. Kasturi S.P. Pulendran B. Moore J.P. Ahmed R. Seumois G. Burton D.R. Sanders R.W. Silvestri G. Crotty S. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer. Cell Rep. 2016 17 9 2195 2209 10.1016/j.celrep.2016.10.085 27880897
    [Google Scholar]
  226. Barnes C.O. Gristick H.B. Freund N.T. Escolano A. Lyubimov A.Y. Hartweger H. West A.P. Jr Cohen A.E. Nussenzweig M.C. Bjorkman P.J. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nat. Commun. 2018 9 1 1251 10.1038/s41467‑018‑03632‑y 29593217
    [Google Scholar]
  227. Pejchal R. Doores K.J. Walker L.M. Khayat R. Huang P.S. Wang S.K. Stanfield R.L. Julien J.P. Ramos A. Crispin M. Depetris R. Katpally U. Marozsan A. Cupo A. Maloveste S. Liu Y. McBride R. Ito Y. Sanders R.W. Ogohara C. Paulson J.C. Feizi T. Scanlan C.N. Wong C.H. Moore J.P. Olson W.C. Ward A.B. Poignard P. Schief W.R. Burton D.R. Wilson I.A. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011 334 6059 1097 1103 10.1126/science.1213256 21998254
    [Google Scholar]
  228. Kumar S. Panda H. Makhdoomi M.A. Mishra N. Safdari H.A. Chawla H. Aggarwal H. Reddy E.S. Lodha R. Kumar Kabra S. Chandele A. Dutta S. Luthra K. An HIV-1 broadly neutralizing antibody from a clade C-infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses. J. Virol. 2019 93 4 01495 18 10.1128/jvi 30429339
    [Google Scholar]
  229. Longo N.S. Sutton M.S. Shiakolas A.R. Guenaga J. Jarosinski M.C. Georgiev I.S. McKee K. Bailer R.T. Louder M.K. O’Dell S. Connors M. Wyatt R.T. Mascola J.R. Doria-Rose N.A. Multiple antibody lineages in one donor target the glycan-V3 supersite of the HIV-1 envelope glycoprotein and display a preference for quaternary binding. J. Virol. 2016 90 23 10574 10586 10.1128/JVI.01012‑16 27654288
    [Google Scholar]
  230. Cai H. Orwenyo J. Guenaga J. Giddens J. Toonstra C. Wyatt R.T. Wang L.X. Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan-dependent HIV-1 broadly neutralizing antibodies. Chem. Commun. 2017 53 39 5453 5456 10.1039/C7CC02059G 28466900
    [Google Scholar]
  231. Zhou T. Zhu J. Yang Y. Gorman J. Ofek G. Srivatsan S. Druz A. Lees C.R. Lu G. Soto C. Stuckey J. Burton D.R. Koff W.C. Connors M. Kwon P.D. Transplanting supersites of HIV-1 vulnerability. PLoS One 2014 9 7 e99881 10.1371/journal.pone.0099881 24992528
    [Google Scholar]
  232. Francica J.R. Laga R. Lynn G.M. Mužíková G. Androvič L. Aussedat B. Walkowicz W.E. Padhan K. Ramirez-Valdez R.A. Parks R. Schmidt S.D. Flynn B.J. Tsybovsky Y. Stewart-Jones G.B.E. Saunders K.O. Baharom F. Petrovas C. Haynes B.F. Seder R.A. Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. PLoS Biol. 2019 17 6 e3000328 10.1371/journal.pbio.3000328 31206510
    [Google Scholar]
  233. Garrity R.R. Rimmelzwaan G. Minassian A. Tsai W.P. Lin G. de Jong J.J. Goudsmit J. Nara P.L. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 1997 159 1 279 289 10.4049/jimmunol.159.1.279 9200464
    [Google Scholar]
  234. Henderson R. Zhou Y. Stalls V. Wiehe K. Saunders K.O. Wagh K. Anasti K. Barr M. Parks R. Alam S.M. Korber B. Haynes B.F. Bartesaghi A. Acharya P. Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage. Nat. Commun. 2023 14 1 2782 10.1038/s41467‑023‑38108‑1 37188681
    [Google Scholar]
  235. Swanson O.M. Zhang Q.E. Van Itallie E. Tian M. Brown A.R. Harris C. Kapingidza A.B. Rhodes B. Smith L.M. Venkatayogi S. Cronin K. Frazier M. Parks R. Bar M. Jiang C. Martin Beem J.S. Cheng H.L. Davis J. McGovern K. Newman A. Edwards R.J. Cain D. Alam S.M. Wiehe K. Saunders K.O. Acharya P. Alt F. Haynes B.F. Azoitei M.L. An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations. Sci. Transl. Med. 2025 17 780 eadr2218 10.1126/scitranslmed.adr2218 39772772
    [Google Scholar]
  236. Doria-Rose N.A. Schramm C.A. Gorman J. Moore P.L. Bhiman J.N. DeKosky B.J. Ernandes M.J. Georgiev I.S. Kim H.J. Pancera M. Staupe R.P. Altae-Tran H.R. Bailer R.T. Crooks E.T. Cupo A. Druz A. Garrett N.J. Hoi K.H. Kong R. Louder M.K. Longo N.S. McKee K. Nonyane M. O’Dell S. Roark R.S. Rudicell R.S. Schmidt S.D. Sheward D.J. Soto C. Wibmer C.K. Yang Y. Zhang Z. Mullikin J.C. Binley J.M. Sanders R.W. Wilson I.A. Moore J.P. Ward A.B. Georgiou G. Williamson C. Abdool Karim S.S. Morris L. Kwong P.D. Shapiro L. Mascola J.R. NISC Comparative Sequencing Program Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014 509 7498 55 62 10.1038/nature13036 24590074
    [Google Scholar]
  237. Sok D. van Gils M.J. Pauthner M. Julien J.P. Saye-Francisco K.L. Hsueh J. Briney B. Lee J.H. Le K.M. Lee P.S. Hua Y. Seaman M.S. Moore J.P. Ward A.B. Wilson I.A. Sanders R.W. Burton D.R. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 2014 111 49 17624 17629 10.1073/pnas.1415789111 25422458
    [Google Scholar]
  238. Gorman J. Soto C. Yang M.M. Davenport T.M. Guttman M. Bailer R.T. Chambers M. Chuang G.Y. DeKosky B.J. Doria-Rose N.A. Druz A. Ernandes M.J. Georgiev I.S. Jarosinski M.C. Joyce M.G. Lemmin T.M. Leung S. Louder M.K. McDaniel J.R. Narpala S. Pancera M. Stuckey J. Wu X. Yang Y. Zhang B. Zhou T. Program N.I.S.C.C.S. Mullikin J.C. Baxa U. Georgiou G. McDermott A.B. Bonsignori M. Haynes B.F. Moore P.L. Morris L. Lee K.K. Shapiro L. Mascola J.R. Kwong P.D. NISC Comparative Sequencing Program Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 2016 23 1 81 90 10.1038/nsmb.3144 26689967
    [Google Scholar]
  239. Doria-Rose N.A. Bhiman J.N. Roark R.S. Schramm C.A. Gorman J. Chuang G.Y. Pancera M. Cale E.M. Ernandes M.J. Louder M.K. Asokan M. Bailer R.T. Druz A. Fraschilla I.R. Garrett N.J. Jarosinski M. Lynch R.M. McKee K. O’Dell S. Pegu A. Schmidt S.D. Staupe R.P. Sutton M.S. Wang K. Wibmer C.K. Haynes B.F. Abdool-Karim S. Shapiro L. Kwong P.D. Moore P.L. Morris L. Mascola J.R. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 2016 90 1 76 91 10.1128/JVI.01791‑15 26468542
    [Google Scholar]
  240. Derdeyn C.A. Moore P.L. Morris L. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr. Opin. HIV AIDS 2014 9 3 210 216 10.1097/COH.0000000000000057 24662931
    [Google Scholar]
  241. Cale E.M. Gorman J. Radakovich N.A. Crooks E.T. Osawa K. Tong T. Li J. Nagarajan R. Ozorowski G. Ambrozak D.R. Asokan M. Bailer R.T. Bennici A.K. Chen X. Doria-Rose N.A. Druz A. Feng Y. Joyce M.G. Louder M.K. O’Dell S. Oliver C. Pancera M. Connors M. Hope T.J. Kepler T.B. Wyatt R.T. Ward A.B. Georgiev I.S. Kwong P.D. Mascola J.R. Binley J.M. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity 2017 46 5 777 791.e10 10.1016/j.immuni.2017.04.011 28514685
    [Google Scholar]
  242. McLellan J.S. Pancera M. Carrico C. Gorman J. Julien J.P. Khayat R. Louder R. Pejchal R. Sastry M. Dai K. O’Dell S. Patel N. Shahzad-ul-Hussan S. Yang Y. Zhang B. Zhou T. Zhu J. Boyington J.C. Chuang G.Y. Diwanji D. Georgiev I. Do Kwon Y. Lee D. Louder M.K. Moquin S. Schmidt S.D. Yang Z.Y. Bonsignori M. Crump J.A. Kapiga S.H. Sam N.E. Haynes B.F. Burton D.R. Koff W.C. Walker L.M. Phogat S. Wyatt R. Orwenyo J. Wang L.X. Arthos J. Bewley C.A. Mascola J.R. Nabel G.J. Schief W.R. Ward A.B. Wilson I.A. Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011 480 7377 336 343 10.1038/nature10696 22113616
    [Google Scholar]
  243. Lee J.H. Andrabi R. Su C.Y. Yasmeen A. Julien J.P. Kong L. Wu N.C. McBride R. Sok D. Pauthner M. Cottrell C.A. Nieusma T. Blattner C. Paulson J.C. Klasse P.J. Wilson I.A. Burton D.R. Ward A.B. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic β-hairpin structure. Immunity 2017 46 4 690 702 10.1016/j.immuni.2017.03.017 28423342
    [Google Scholar]
  244. Gorman J. Chuang G.Y. Lai Y.T. Shen C.H. Boyington J.C. Druz A. Geng H. Louder M.K. McKee K. Rawi R. Verardi R. Yang Y. Zhang B. Doria-Rose N.A. Lin B. Moore P.L. Morris L. Shapiro L. Mascola J.R. Kwong P.D. Structure of super-potent antibody CAP256-VRC26. 25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition. Cell Rep. 2020 31 1 107488 10.1016/j.celrep.2020.03.052 32268107
    [Google Scholar]
  245. Andrabi R. Voss J.E. Liang C.H. Briney B. McCoy L.E. Wu C.Y. Wong C.H. Poignard P. Burton D.R. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 2015 43 5 959 973 10.1016/j.immuni.2015.10.014 26588781
    [Google Scholar]
  246. Sliepen K. Medina-Ramírez M. Yasmeen A. Moore J.P. Klasse P.J. Sanders R.W. Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology 2015 486 116 120 10.1016/j.virol.2015.08.002 26433050
    [Google Scholar]
  247. Andrabi R. Pallesen J. Allen J.D. Song G. Zhang J. de Val N. Gegg G. Porter K. Su C.Y. Pauthner M. Newman A. Bouton-Verville H. Garces F. Wilson I.A. Crispin M. Hahn B.H. Haynes B.F. Verkoczy L. Ward A.B. Burton D.R. The chimpanzee SIV envelope trimer: Structure and deployment as an HIV vaccine template. Cell Rep. 2019 27 8 2426 2441.e6 10.1016/j.celrep.2019.04.082 31116986
    [Google Scholar]
  248. Bibollet-Ruche F. Russell R.M. Ding W. Liu W. Li Y. Wagh K. Wrapp D. Habib R. Skelly A.N. Roark R.S. Sherrill-Mix S. Wang S. Rando J. Lindemuth E. Cruickshank K. Park Y. Baum R. Carey J.W. Connell A.J. Li H. Giorgi E.E. Song G.S. Ding S. Finzi A. Newman A. Hernandez G.E. Machiele E. Cain D.W. Mansouri K. Lewis M.G. Montefiori D.C. Wiehe K.J. Alam S.M. Teng I.T. Kwong P.D. Andrabi R. Verkoczy L. Burton D.R. Korber B.T. Saunders K.O. Haynes B.F. Edwards R.J. Shaw G.M. Hahn B.H. A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies. MBio 2023 14 1 e03370-22 10.1128/mbio.03370‑22 36629414
    [Google Scholar]
  249. Saunders K.O. Verkoczy L.K. Jiang C. Zhang J. Parks R. Chen H. Housman M. Bouton-Verville H. Shen X. Trama A.M. Scearce R. Sutherland L. Santra S. Newman A. Eaton A. Xu K. Georgiev I.S. Joyce M.G. Tomaras G.D. Bonsignori M. Reed S.G. Salazar A. Mascola J.R. Moody M.A. Cain D.W. Centlivre M. Zurawski S. Zurawski G. Erickson H.P. Kwong P.D. Alam S.M. Levy Y. Montefiori D.C. Haynes B.F. Vaccine induction of heterologous tier 2 HIV-1 neutralizing antibodies in animal models. Cell Rep. 2017 21 13 3681 3690 10.1016/j.celrep.2017.12.028 29281818
    [Google Scholar]
  250. Kong R. Xu K. Zhou T. Acharya P. Lemmin T. Liu K. Ozorowski G. Soto C. Taft J.D. Bailer R.T. Cale E.M. Chen L. Choi C.W. Chuang G.Y. Doria-Rose N.A. Druz A. Georgiev I.S. Gorman J. Huang J. Joyce M.G. Louder M.K. Ma X. McKee K. O’Dell S. Pancera M. Yang Y. Blanchard S.C. Mothes W. Burton D.R. Koff W.C. Connors M. Ward A.B. Kwong P.D. Mascola J.R. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 2016 352 6287 828 833 10.1126/science.aae0474 27174988
    [Google Scholar]
  251. Cheng C. Duan H. Xu K. Chuang G.Y. Corrigan A.R. Geng H. O’Dell S. Ou L. Chambers M. Changela A. Chen X. Foulds K.E. Sarfo E.K. Jafari A.J. Hill K.R. Kong R. Liu K. Todd J.P. Tsybovsky Y. Verardi R. Wang S. Wang Y. Wu W. Zhou T. Arnold F.J. Doria-Rose N.A. Koup R.A. McDermott A.B. Scorpio D.G. Worobey M. Shapiro L. Mascola J.R. Kwong P.D. VRC Production Program Immune monitoring reveals fusion peptide priming to imprint cross-clade HIV-neutralizing responses with a characteristic early B cell signature. Cell Rep. 2020 32 5 107981 10.1016/j.celrep.2020.107981 32755575
    [Google Scholar]
  252. van Gils M.J. van den Kerkhof T.L.G.M. Ozorowski G. Cottrell C.A. Sok D. Pauthner M. Pallesen J. de Val N. Yasmeen A. de Taeye S.W. Schorcht A. Gumbs S. Johanna I. Saye-Francisco K. Liang C.H. Landais E. Nie X. Pritchard L.K. Crispin M. Kelsoe G. Wilson I.A. Schuitemaker H. Klasse P.J. Moore J.P. Burton D.R. Ward A.B. Sanders R.W. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat. Microbiol. 2016 2 2 16199 10.1038/nmicrobiol.2016.199 27841852
    [Google Scholar]
  253. Cottrell C.A. van Schooten J. Bowman C.A. Yuan M. Oyen D. Shin M. Morpurgo R. van der Woude P. van Breemen M. Torres J.L. Patel R. Gross J. Sewall L.M. Copps J. Ozorowski G. Nogal B. Sok D. Rakasz E.G. Labranche C. Vigdorovich V. Christley S. Carnathan D.G. Sather D.N. Montefiori D. Silvestri G. Burton D.R. Moore J.P. Wilson I.A. Sanders R.W. Ward A.B. van Gils M.J. Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS Pathog. 2020 16 8 e1008753 10.1371/journal.ppat.1008753 32866207
    [Google Scholar]
  254. Nogal B. Bianchi M. Cottrell C.A. Kirchdoerfer R.N. Sewall L.M. Turner H.L. Zhao F. Sok D. Burton D.R. Hangartner L. Ward A.B. Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines. Cell Rep. 2020 30 11 3755 3765.e7 10.1016/j.celrep.2020.02.061 32187547
    [Google Scholar]
  255. Yuan M. Cottrell C.A. Ozorowski G. van Gils M.J. Kumar S. Wu N.C. Sarkar A. Torres J.L. de Val N. Copps J. Moore J.P. Sanders R.W. Ward A.B. Wilson I.A. Conformational plasticity in the HIV-1 fusion peptide facilitates recognition by broadly neutralizing antibodies. Cell Host Microbe 2019 25 6 873 883.e5 10.1016/j.chom.2019.04.011 31194940
    [Google Scholar]
  256. Kong R. Duan H. Sheng Z. Xu K. Acharya P. Chen X. Cheng C. Dingens A.S. Gorman J. Sastry M. Shen C.H. Zhang B. Zhou T. Chuang G.Y. Chao C.W. Gu Y. Jafari A.J. Louder M.K. O’Dell S. Rowshan A.P. Viox E.G. Wang Y. Choi C.W. Corcoran M.M. Corrigan A.R. Dandey V.P. Eng E.T. Geng H. Foulds K.E. Guo Y. Kwon Y.D. Lin B. Liu K. Mason R.D. Nason M.C. Ohr T.Y. Ou L. Rawi R. Sarfo E.K. Schön A. Todd J.P. Wang S. Wei H. Wu W. Mullikin J.C. Bailer R.T. Doria-Rose N.A. Karlsson Hedestam G.B. Scorpio D.G. Overbaugh J. Bloom J.D. Carragher B. Potter C.S. Shapiro L. Kwong P.D. Mascola J.R. NISC Comparative Sequencing Program Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization. Cell 2019 178 3 567 584.e19 10.1016/j.cell.2019.06.030 31348886
    [Google Scholar]
  257. Cheng C. Xu K. Kong R. Chuang G.Y. Corrigan A.R. Geng H. Hill K.R. Jafari A.J. O’Dell S. Ou L. Rawi R. Rowshan A.P. Sarfo E.K. Sastry M. Saunders K.O. Schmidt S.D. Wang S. Wu W. Zhang B. Doria-Rose N.A. Haynes B.F. Scorpio D.G. Shapiro L. Mascola J.R. Kwong P.D. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. PLoS One 2019 14 4 e0215163 10.1371/journal.pone.0215163 30995238
    [Google Scholar]
  258. Xu K. Acharya P. Kong R. Cheng C. Chuang G.Y. Liu K. Louder M.K. O’Dell S. Rawi R. Sastry M. Shen C.H. Zhang B. Zhou T. Asokan M. Bailer R.T. Chambers M. Chen X. Choi C.W. Dandey V.P. Doria-Rose N.A. Druz A. Eng E.T. Farney S.K. Foulds K.E. Geng H. Georgiev I.S. Gorman J. Hill K.R. Jafari A.J. Kwon Y.D. Lai Y.T. Lemmin T. McKee K. Ohr T.Y. Ou L. Peng D. Rowshan A.P. Sheng Z. Todd J.P. Tsybovsky Y. Viox E.G. Wang Y. Wei H. Yang Y. Zhou A.F. Chen R. Yang L. Scorpio D.G. McDermott A.B. Shapiro L. Carragher B. Potter C.S. Mascola J.R. Kwong P.D. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 2018 24 6 857 867 10.1038/s41591‑018‑0042‑6 29867235
    [Google Scholar]
  259. Zhang L. Irimia A. He L. Landais E. Rantalainen K. Leaman D.P. Vollbrecht T. Stano A. Sands D.I. Kim A.S. Miiro G. Serwanga J. Pozniak A. McPhee D. Manigart O. Mwananyanda L. Karita E. Inwoley A. Jaoko W. DeHovitz J. Bekker L-G. Pitisuttithum P. Paris R. Allen S. Poignard P. Burton D.R. Murrell B. Ward A.B. Zhu J. Wilson I.A. Zwick M.B. IAVI Protocol G Investigators An MPER antibody neutralizes HIV-1 using germline features shared among donors. Nat. Commun. 2019 10 1 5389 10.1038/s41467‑019‑12973‑1 31772165
    [Google Scholar]
  260. Stiegler G. Kunert R. Purtscher M. Wolbank S. Voglauer R. Steindl F. Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001 17 18 1757 1765 10.1089/08892220152741450 11788027
    [Google Scholar]
  261. Zwick M.B. Labrijn A.F. Wang M. Spenlehauer C. Saphire E.O. Binley J.M. Moore J.P. Stiegler G. Katinger H. Burton D.R. Parren P.W.H.I. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001 75 22 10892 10905 10.1128/JVI.75.22.10892‑10905.2001 11602729
    [Google Scholar]
  262. Huang J. Ofek G. Laub L. Louder M.K. Doria-Rose N.A. Longo N.S. Imamichi H. Bailer R.T. Chakrabarti B. Sharma S.K. Alam S.M. Wang T. Yang Y. Zhang B. Migueles S.A. Wyatt R. Haynes B.F. Kwong P.D. Mascola J.R. Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012 491 7424 406 412 10.1038/nature11544 23151583
    [Google Scholar]
  263. Krebs S.J. Kwon Y.D. Schramm C.A. Law W.H. Donofrio G. Zhou K.H. Gift S. Dussupt V. Georgiev I.S. Schätzle S. McDaniel J.R. Lai Y.T. Sastry M. Zhang B. Jarosinski M.C. Ransier A. Chenine A.L. Asokan M. Bailer R.T. Bose M. Cagigi A. Cale E.M. Chuang G.Y. Darko S. Driscoll J.I. Druz A. Gorman J. Laboune F. Louder M.K. McKee K. Mendez L. Moody M.A. O’Sullivan A.M. Owen C. Peng D. Rawi R. Sanders-Buell E. Shen C.H. Shiakolas A.R. Stephens T. Tsybovsky Y. Tucker C. Verardi R. Wang K. Zhou J. Zhou T. Georgiou G. Alam S.M. Haynes B.F. Rolland M. Matyas G.R. Polonis V.R. McDermott A.B. Douek D.C. Shapiro L. Tovanabutra S. Michael N.L. Mascola J.R. Robb M.L. Kwong P.D. Doria-Rose N.A. Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual. Immunity 2019 50 3 677 691.e13 10.1016/j.immuni.2019.02.008 30876875
    [Google Scholar]
  264. Pinto D. Fenwick C. Caillat C. Silacci C. Guseva S. Dehez F. Chipot C. Barbieri S. Minola A. Jarrossay D. Tomaras G.D. Shen X. Riva A. Tarkowski M. Schwartz O. Bruel T. Dufloo J. Seaman M.S. Montefiori D.C. Lanzavecchia A. Corti D. Pantaleo G. Weissenhorn W. Structural basis for broad HIV-1 neutralization by the MPER-specific human broadly neutralizing antibody LN01. Cell Host Microbe 2019 26 5 623 637.e8 10.1016/j.chom.2019.09.016 31653484
    [Google Scholar]
  265. Williams L.D. Ofek G. Schätzle S. McDaniel J.R. Lu X. Nicely N.I. Wu L. Lougheed C.S. Bradley T. Louder M.K. McKee K. Bailer R.T. O’Dell S. Georgiev I.S. Seaman M.S. Parks R.J. Marshall D.J. Anasti K. Yang G. Nie X. Tumba N.L. Wiehe K. Wagh K. Korber B. Kepler T.B. Munir Alam S. Morris L. Kamanga G. Cohen M.S. Bonsignori M. Xia S.M. Montefiori D.C. Kelsoe G. Gao F. Mascola J.R. Moody M.A. Saunders K.O. Liao H.X. Tomaras G.D. Georgiou G. Haynes B.F. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol. 2017 2 7 eaal2200 10.1126/sciimmunol.aal2200 28783671
    [Google Scholar]
  266. Haynes B.F. Fleming J. St Clair E.W. Katinger H. Stiegler G. Kunert R. Robinson J. Scearce R.M. Plonk K. Staats H.F. Ortel T.L. Liao H.X. Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005 308 5730 1906 1908 10.1126/science.1111781 15860590
    [Google Scholar]
  267. Yang G. Holl T.M. Liu Y. Li Y. Lu X. Nicely N.I. Kepler T.B. Alam S.M. Liao H.X. Cain D.W. Spicer L. VandeBerg J.L. Haynes B.F. Kelsoe G. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 2013 210 2 241 256 10.1084/jem.20121977 23359068
    [Google Scholar]
  268. Alam S.M. Morelli M. Dennison S.M. Liao H.X. Zhang R. Xia S.M. Rits-Volloch S. Sun L. Harrison S.C. Haynes B.F. Chen B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 2009 106 48 20234 20239 10.1073/pnas.0908713106 19906992
    [Google Scholar]
  269. Alam S.M. McAdams M. Boren D. Rak M. Scearce R.M. Gao F. Camacho Z.T. Gewirth D. Kelsoe G. Chen P. Haynes B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 2007 178 7 4424 4435 10.4049/jimmunol.178.7.4424 17372000
    [Google Scholar]
  270. Chen J. Frey G. Peng H. Rits-Volloch S. Garrity J. Seaman M.S. Chen B. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 2014 88 2 1249 1258 10.1128/JVI.02664‑13 24227838
    [Google Scholar]
  271. Alam S.M. Liao H.X. Dennison S.M. Jaeger F. Parks R. Anasti K. Foulger A. Donathan M. Lucas J. Verkoczy L. Nicely N. Tomaras G.D. Kelsoe G. Chen B. Kepler T.B. Haynes B.F. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 2011 85 22 11725 11731 10.1128/JVI.05680‑11 21917975
    [Google Scholar]
  272. Erdmann N.B. A hiv-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals. medRxiv 2024 10.1101/2024.03.15.24304305
    [Google Scholar]
  273. Williams W.B. Alam S.M. Ofek G. Erdmann N. Montefiori D.C. Seaman M.S. Wagh K. Korber B. Edwards R.J. Mansouri K. Eaton A. Cain D.W. Martin M. Hwang J. Arus-Altuz A. Lu X. Cai F. Jamieson N. Parks R. Barr M. Foulger A. Anasti K. Patel P. Sammour S. Parsons R.J. Huang X. Lindenberger J. Fetics S. Janowska K. Niyongabo A. Janus B.M. Astavans A. Fox C.B. Mohanty I. Evangelous T. Chen Y. Berry M. Kirshner H. Van Itallie E. Saunders K.O. Wiehe K. Cohen K.W. McElrath M.J. Corey L. Acharya P. Walsh S.R. Baden L.R. Haynes B.F. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. Cell 2024 187 12 2919 2934.e20 10.1016/j.cell.2024.04.033 38761800
    [Google Scholar]
  274. Irimia A. Serra A.M. Sarkar A. Jacak R. Kalyuzhniy O. Sok D. Saye-Francisco K.L. Schiffner T. Tingle R. Kubitz M. Adachi Y. Stanfield R.L. Deller M.C. Burton D.R. Schief W.R. Wilson I.A. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog. 2017 13 2 e1006212 10.1371/journal.ppat.1006212 28225819
    [Google Scholar]
  275. Mkhize N.N. Yssel A.E.J. Kaldine H. van Dorsten R.T. Woodward Davis A.S. Beaume N. Matten D. Lambson B. Modise T. Kgagudi P. York T. Westfall D.H. Giorgi E.E. Korber B. Anthony C. Mapengo R.E. Bekker V. Domin E. Eaton A. Deng W. DeCamp A. Huang Y. Gilbert P.B. Gwashu-Nyangiwe A. Thebus R. Ndabambi N. Mielke D. Mgodi N. Karuna S. Edupuganti S. Seaman M.S. Corey L. Cohen M.S. Hural J. McElrath M.J. Mullins J.I. Montefiori D. Moore P.L. Williamson C. Morris L. Neutralization profiles of HIV-1 viruses from the VRC01 antibody mediated prevention (AMP) trials. PLoS Pathog. 2023 19 6 e1011469 10.1371/journal.ppat.1011469 37384759
    [Google Scholar]
  276. Gristick H.B. Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes. bioRxiv 2025 2025.01
    [Google Scholar]
  277. Gristick H.B. Hartweger H. Loewe M. van Schooten J. Ramos V. Oliveira T.Y. Nishimura Y. Koranda N.S. Wall A. Yao K.H. Poston D. Gazumyan A. Wiatr M. Horning M. Keeffe J.R. Hoffmann M.A.G. Yang Z. Abernathy M.E. Dam K.M.A. Gao H. Gnanapragasam P.N.P. Kakutani L.M. Pavlovitch-Bedzyk A.J. Seaman M.S. Howarth M. McGuire A.T. Stamatatos L. Martin M.A. West A.P. Jr Nussenzweig M.C. Bjorkman P.J. CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals. Sci. Immunol. 2023 8 80 eade6364 10.1126/sciimmunol.ade6364 36763635
    [Google Scholar]
  278. Markowitz L.E. Drolet M. Perez N. Jit M. Brisson M. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine 2018 36 32 4806 4815 10.1016/j.vaccine.2018.01.057 29802000
    [Google Scholar]
  279. Ogholikhan S. Schwarz K. Hepatitis vaccines. Vaccines 2016 4 1 6 10.3390/vaccines4010006 26978406
    [Google Scholar]
  280. Inoue T. Moran I. Shinnakasu R. Phan T.G. Kurosaki T. Generation of memory B cells and their reactivation. Immunol. Rev. 2018 283 1 138 149 10.1111/imr.12640 29664566
    [Google Scholar]
  281. Briney B. Sok D. Jardine J.G. Kulp D.W. Skog P. Menis S. Jacak R. Kalyuzhniy O. de Val N. Sesterhenn F. Le K.M. Ramos A. Jones M. Saye-Francisco K.L. Blane T.R. Spencer S. Georgeson E. Hu X. Ozorowski G. Adachi Y. Kubitz M. Sarkar A. Wilson I.A. Ward A.B. Nemazee D. Burton D.R. Schief W.R. Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell 2016 166 6 1459 1470.e11 10.1016/j.cell.2016.08.005 27610570
    [Google Scholar]
  282. Chen X. Zhou T. Schmidt S.D. Duan H. Cheng C. Chuang G.Y. Gu Y. Louder M.K. Lin B.C. Shen C.H. Sheng Z. Zheng M.X. Doria-Rose N.A. Joyce M.G. Shapiro L. Tian M. Alt F.W. Kwong P.D. Mascola J.R. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Immunity 2021 54 2 324 339.e8 10.1016/j.immuni.2020.12.014 33453152
    [Google Scholar]
  283. Wagh K. Kreider E.F. Li Y. Barbian H.J. Learn G.H. Giorgi E. Hraber P.T. Decker T.G. Smith A.G. Gondim M.V. Gillis L. Wandzilak J. Chuang G.Y. Rawi R. Cai F. Pellegrino P. Williams I. Overbaugh J. Gao F. Kwong P.D. Haynes B.F. Shaw G.M. Borrow P. Seaman M.S. Hahn B.H. Korber B. Completeness of HIV-1 envelope glycan shield at transmission determines neutralization breadth. Cell Rep. 2018 25 4 893 908.e7 10.1016/j.celrep.2018.09.087 30355496
    [Google Scholar]
  284. Turner H.L. Andrabi R. Cottrell C.A. Richey S.T. Song G. Callaghan S. Anzanello F. Moyer T.J. Abraham W. Melo M. Silva M. Scaringi N. Rakasz E.G. Sattentau Q.J. Irvine D.J. Burton D.R. Ward A.B. Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. Sci. Adv. 2021 7 31 eabh2791 10.1126/sciadv.abh2791 34321200
    [Google Scholar]
  285. Briney B.S. Willis J.R. Crowe J.E. Jr Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 2012 7 5 e36750 10.1371/journal.pone.0036750 22590602
    [Google Scholar]
  286. del Moral-Sánchez I. Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. npj. Vaccines 2024 9 1 74 38250887
    [Google Scholar]
  287. Schiffner T. Diverse competitor B cell responses to a germline-targeting priming immunogen in human Ig loci transgenic mice. bioRxiv 2024 2024.01
    [Google Scholar]
  288. Hwang J.K. Wang C. Du Z. Meyers R.M. Kepler T.B. Neuberg D. Kwong P.D. Mascola J.R. Joyce M.G. Bonsignori M. Haynes B.F. Yeap L.S. Alt F.W. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 2017 114 32 8614 8619 10.1073/pnas.1709203114 28747530
    [Google Scholar]
  289. Keele B.F. Giorgi E.E. Salazar-Gonzalez J.F. Decker J.M. Pham K.T. Salazar M.G. Sun C. Grayson T. Wang S. Li H. Wei X. Jiang C. Kirchherr J.L. Gao F. Anderson J.A. Ping L.H. Swanstrom R. Tomaras G.D. Blattner W.A. Goepfert P.A. Kilby J.M. Saag M.S. Delwart E.L. Busch M.P. Cohen M.S. Montefiori D.C. Haynes B.F. Gaschen B. Athreya G.S. Lee H.Y. Wood N. Seoighe C. Perelson A.S. Bhattacharya T. Korber B.T. Hahn B.H. Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008 105 21 7552 7557 10.1073/pnas.0802203105 18490657
    [Google Scholar]
  290. Otsuka Y. Schmitt K. Quinlan B.D. Gardner M.R. Alfant B. Reich A. Farzan M. Choe H. Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. PLoS Pathog. 2018 14 8 e1007238 10.1371/journal.ppat.1007238 30125330
    [Google Scholar]
  291. Zhang D. Liu Z. Wang W. Chen M.X. Hou J.L. Zhang Z. Ren W.H. Ren L. Hao Y.L. Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 B′ subtype infected individual with broadly neutralization activity. Mol. Immunol. 2022 145 50 58 10.1016/j.molimm.2022.02.021 35290812
    [Google Scholar]
  292. Umotoy J. Bagaya B.S. Joyce C. Schiffner T. Menis S. Saye-Francisco K.L. Biddle T. Mohan S. Vollbrecht T. Kalyuzhniy O. Madzorera S. Kitchin D. Lambson B. Nonyane M. Kilembe W. Poignard P. Schief W.R. Burton D.R. Murrell B. Moore P.L. Briney B. Sok D. Landais E. IAVI Protocol C Investigators IAVI African HIV Research Network Rapid and focused maturation of a VRC01-class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-glycan. Immunity 2019 51 1 141 154.e6 10.1016/j.immuni.2019.06.004 31315032
    [Google Scholar]
  293. Aldon Y. McKay P.F. Moreno Herrero J. Vogel A.B. Lévai R. Maisonnasse P. Dereuddre-Bosquet N. Haas H. Fábián K. Le Grand R. Sahin U. Shattock R.J. Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA. Mol. Ther. Nucleic Acids 2021 25 483 493 10.1016/j.omtn.2021.06.008 34589271
    [Google Scholar]
  294. Xie C. Yao R. Xia X. The advances of adjuvants in mRNA vaccines. npj. Vaccines 2023 8 1 162 36680007
    [Google Scholar]
  295. Ewer K.J. Lambe T. Rollier C.S. Spencer A.J. Hill A.V.S. Dorrell L. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr. Opin. Immunol. 2016 41 47 54 10.1016/j.coi.2016.05.014 27286566
    [Google Scholar]
  296. Kerstetter L.J. Buckley S. Bliss C.M. Coughlan L. Adenoviral vectors as vaccines for emerging avian influenza viruses. Front. Immunol. 2021 11 607333 10.3389/fimmu.2020.607333 33633727
    [Google Scholar]
  297. Wilmschen S. Schmitz J.E. Kimpel J. Viral vectors for the induction of broadly neutralizing antibodies against HIV. Vaccines 2019 7 3 119 10.3390/vaccines7030119 31546894
    [Google Scholar]
  298. Borst A.J. Weidle C.E. Gray M.D. Frenz B. Snijder J. Joyce M.G. Georgiev I.S. Stewart-Jones G.B.E. Kwong P.D. McGuire A.T. DiMaio F. Stamatatos L. Pancera M. Veesler D. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. eLife 2018 7 e37688 10.7554/eLife.37688 30403372
    [Google Scholar]
  299. Zhou T. Zhu J. Wu X. Moquin S. Zhang B. Acharya P. Georgiev I.S. Altae-Tran H.R. Chuang G.Y. Joyce M.G. Do Kwon Y. Longo N.S. Louder M.K. Luongo T. McKee K. Schramm C.A. Skinner J. Yang Y. Yang Z. Zhang Z. Zheng A. Bonsignori M. Haynes B.F. Scheid J.F. Nussenzweig M.C. Simek M. Burton D.R. Koff W.C. Mullikin J.C. Connors M. Shapiro L. Nabel G.J. Mascola J.R. Kwong P.D. NISC Comparative Sequencing Program Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013 39 2 245 258 10.1016/j.immuni.2013.04.012 23911655
    [Google Scholar]
  300. Shaw G.M. Hahn B.H. Arya S.K. Groopman J.E. Gallo R.C. Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984 226 4679 1165 1171 10.1126/science.6095449 6095449
    [Google Scholar]
  301. Ratner L. Haseltine W. Patarca R. Livak K.J. Starcich B. Josephs S.F. Doran E.R. Rafalski J.A. Whitehorn E.A. Baumeister K. Ivanoff L. Petteway S.R. Jr Pearson M.L. Lautenberger J.A. Papas T.S. Ghrayeb J. Chang N.T. Gallo R.C. Wong-Staal F. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985 313 6000 277 284 10.1038/313277a0 2578615
    [Google Scholar]
  302. Seaman M.S. Janes H. Hawkins N. Grandpre L.E. Devoy C. Giri A. Coffey R.T. Harris L. Wood B. Daniels M.G. Bhattacharya T. Lapedes A. Polonis V.R. McCutchan F.E. Gilbert P.B. Self S.G. Korber B.T. Montefiori D.C. Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010 84 3 1439 1452 10.1128/JVI.02108‑09 19939925
    [Google Scholar]
  303. Bennett N.R. Atomically accurate de novo design of single-domain antibodies. bioRxiv 2024
    [Google Scholar]
  304. Watson J.L. Juergens D. Bennett N.R. Trippe B.L. Yim J. Eisenach H.E. Ahern W. Borst A.J. Ragotte R.J. Milles L.F. Wicky B.I.M. Hanikel N. Pellock S.J. Courbet A. Sheffler W. Wang J. Venkatesh P. Sappington I. Torres S.V. Lauko A. De Bortoli V. Mathieu E. Ovchinnikov S. Barzilay R. Jaakkola T.S. DiMaio F. Baek M. Baker D. De novo design of protein structure and function with RFdiffusion. Nature 2023 620 7976 1089 1100 10.1038/s41586‑023‑06415‑8 37433327
    [Google Scholar]
  305. Dauparas J. Anishchenko I. Bennett N. Bai H. Ragotte R.J. Milles L.F. Wicky B.I.M. Courbet A. de Haas R.J. Bethel N. Leung P.J.Y. Huddy T.F. Pellock S. Tischer D. Chan F. Koepnick B. Nguyen H. Kang A. Sankaran B. Bera A.K. King N.P. Baker D. Robust deep learning–based protein sequence design using ProteinMPNN. Science 2022 378 6615 49 56 10.1126/science.add2187 36108050
    [Google Scholar]
  306. Abramson J. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024 1 3
    [Google Scholar]
/content/journals/chr/10.2174/011570162X365229250527111140
Loading
Germline-Targeting Strategies to Induce bNAbs against HIV-1
Bentham Science Publishers ; https://doi.org/10.2174/011570162X365229250527111140
/content/journals/chr/10.2174/011570162X365229250527111140
/content/journals/chr/10.2174/011570162X365229250527111140
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: B-cell ; Germline-Targeting ; broadly neutralizing antibodies ; HIV-1 ; Env glycoprotein ; vaccine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test